0001213900-19-017900.txt : 20190913 0001213900-19-017900.hdr.sgml : 20190913 20190912185441 ACCESSION NUMBER: 0001213900-19-017900 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20190731 FILED AS OF DATE: 20190913 DATE AS OF CHANGE: 20190912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NutriBand Inc. CENTRAL INDEX KEY: 0001676047 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 811118176 STATE OF INCORPORATION: NV FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55644 FILM NUMBER: 191091272 BUSINESS ADDRESS: STREET 1: 121 S. ORANGE AVE. STREET 2: SUITE 1500 CITY: ORLANDO STATE: FL ZIP: 32801 BUSINESS PHONE: 407 377-6695 MAIL ADDRESS: STREET 1: 121 S. ORANGE AVE. STREET 2: SUITE 1500 CITY: ORLANDO STATE: FL ZIP: 32801 FORMER COMPANY: FORMER CONFORMED NAME: Nutriband Inc. DATE OF NAME CHANGE: 20160601 10-Q 1 f10q0719_nutribandinc.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2019

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number 000-55654

NUTRIBAND INC.

(Exact name of registrant as specified in its charter)

NEVADA		81-1118176
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

121 South Orange Ave., Suite 1500, Orlando, FL		32801
(Address of Principal Executive Offices)		(Zip Code)

(407) 377-6695

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the issuer’s common stock, par value $0.001 per share, was 5,423,956 as of September 11, 2019.

NUTRIBAND INC.

INDEX

		Page No.
Part I: Financial Information		1

Item 1	Financial Statements	1
	Consolidated Balance Sheets as of July 31, 2019 (unaudited) and January 31, 2019	1
	Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and six months ended July 31, 2019 and 2018	2
	Unaudited Consolidated Statements of Stockholders Equity for the three and six months ended July 31, 2019 and 2018	3
	Unaudited Consolidated Statements of Cash Flows for the six months ended July 31, 2019 and 2018	5
	Notes to Unaudited Consolidated Financial Statements	6
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3	Quantitative and Qualitative Disclosures about Market Risk	20
Item 4	Controls and Procedures	21

Part II: Other Information		21
Item 5	Other Information	22
Item 6	Exhibits	22

FORWARD LOOKING STATEMENTS

This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future matters are forward-looking statements.

Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our annual report on Form 10-K for the year ended January 31, 2018, in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q and information contained in other reports that we file with the SEC. You are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.

We file reports with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.

We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

References to “we,” “us,” “our” and words of like import refer to Nutriband Inc. and its subsidiaries unless the context indicates otherwise. Unless the context indicates otherwise, references to 4P Therapeutics relate to the operations of 4P Therapeutics LLC prior to our acquisition of 4P Therapeutics on August 1, 2018.

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

NUTRIBAND INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	July 31,			January 31,
	2019			2019
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	13,833		$	474,653
Accounts receivable		70,542			13,088
Prepaid expenses		68,500			102,725
Total Current Assets		152,875			590,466

PROPERTY & EQUIPMENT-net		128,588			146,147

OTHER ASSETS:
Goodwill		1,719,235			1,719,235
Right of use asset-net		19,218			-
Intangible assets-net		333,235			351,770

TOTAL ASSETS	$	2,353,151		$	2,807,618

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	610,357		$	291,781
Customer deposits		-			71,225
Operating lease liability		19,652			-
Note payable		90,000			40,000

Total Current Liabilities		720,009			403,006

Commitments and Contingencies		-			-

STOCKHOLDERS' EQUITY:
Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding		-			-
Common stock, $.001 par value, 25,000,000 shares authorized; 5,423,956 shares issued and outstanding at July 31, 2019 and January 31, 2019		5,424			5,424
Additional paid-in-capital		8,832,590			8,579,890
Accumulated other comprehensive loss		(304	)		(52	)
Accumulated deficit		(7,204,568	)		(6,180,650	)
Total Stockholders' Equity		1,633,142			2,404,612

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	2,353,151		$	2,807,618

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

	Three Months Ended						Six Months Ended
	July 31,						July 31,
	2019			2018			2019			2018

Revenue	$	74,913		$	-		$	268,503		$	-

Costs and expenses:
Cost of revenues		117,959			-			316,753			-
Selling, general and administrative expenses		406,566			1,878,772			974,523			2,326,870
Total Costs and Expenses		524,525			1,878,772			1,291,276			2,326,870

Loss from operations		(449,612	)		(1,878,772	)		(1,022,773	)		(2,326,870	)

Other income (expense)
Interest expense		(953	)		-			(1,145	)		-

Loss from operations before provision for income taxes		(450,565	)		(1,878,772	)		(1,023,918	)		(2,326,870	)

Provision for income taxes		-			-			-			-

Net loss	$	(450,565	)	$	(1,878,772	)	$	(1,023,918	)	$	(2,326,870	)


Net loss per share of common stock-basic and diluted	$	(0.08	)	$	(0.36	)	$	(0.19	)	$	(0.44	)

Weighted average shares of common stock outstanding - basic and diluted		5,423,956			5,310,033			5,423,956			5,265,406

Other Comprehensive Income (Loss):

Net loss	$	(573,353	)	$	(1,878,772	)	$	(1,023,918	)	$	(2,326,870	)

Foreign currency translation adjustment		-			252			(252	)		398

Total Comprehensive Income (Loss)	$	(573,353	)	$	(1,878,520	)	$	(1,024,170	)	$	(2,326,472	)

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

Six Months Ended July 31, 2018										Accumulated
				Common Stock				Additional		Other
				Number of				Paid In		Comprehensive			Accumulated
	Total			shares		Amount		Capital		Income(Loss)			Deficit
Balance, February 1, 2018	$	121,508			5,219,275	$	5,219	$	2,966,145	$	(446	)	$	(2,849,410	)

Issuance of common stock for services		1,763,950			80,500		80		1,763,870		-			-

Sale of common stock for cash		1,000,000			62,500		63		999,937		-			-

Common stock issued upon the exercise of warrants		500,000			31,250		31		499,969		-			-

Common stock issued for acquisition		1,850,000			62,500		63		1,849,937		-			-

Foreign currency translation adjustment		398			-		-		-		398			-

Net loss for the six months ended July 31, 2018		(2,326,870	)		-		-		-		-			(2,326,870	)

Balance, July 31, 2018	$	2,908,986			5,456,025	$	5,456	$	8,079,858	$	(48	)	$	(5,176,280	)

Six Months Ended July 31, 2019
										Accumulated
				Common Stock				Additional		Other
				Number of				Paid In		Comprehensive			Accumulated
	Total			shares		Amount		Capital		Income(Loss)			Deficit
Balance, February 1, 2019	$	2,404,612			5,423,956	$	5,424	$	8,579,890	$	(52	)	$	(6,180,650	)

Issuance of warrants for services		252,700			-		-		252,700		-			-

Net loss for the six months ended July 31, 2019		(1,023,918	)		-		-		-		-			(1,023,918	)

Foreign currency translation adjustment		(252	)		-		-		-		(252	)		-

Balance, July 31, 2019	$	1,633,142			5,423,956	$	5,424	$	8,832,590	$	(304	)	$	(7,204,568	)

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

Three Months Ended July 31, 2018										Accumulated
				Common Stock				Additional		Other						Common
				Number of				Paid In		Comprehensive			Accumulated			stock
	Total			shares		Amount		Capital		Income(Loss)			Deficit			to be issued
Balance, April 30, 2018	$	(48,944	)		5,219,275	$	5,219	$	2,966,145	$	(300	)	$	(3,297,508	)	$	277,500

Issuance of common stock for services		1,486,450			80,500		80		1,763,870		-			-			(277,500	)

Sale of common stock for cash		1,000,000			62,500		63		999,937		-			-			-

Common stock issued upon the exercise of warrants		500,000			31,250		31		499,969		-			-			-

Common stock issued for acquisition		1,850,000			62,500		63		1,849,937		-			-			-

Foreign currency translation adjustment		252			-		-		-		252			-			-

Net loss for the three months ended July 31, 2018		(1,878,772	)		-		-		-		-			(1,878,772	)		-

Balance, July 31, 2018	$	2,908,986			5,456,025	$	5,456	$	8,079,858	$	(48	)	$	(5,176,280	)	$	-

Three Months Ended July 31, 2019										Accumulated
				Common Stock				Additional		Other
				Number of				Paid In		Comprehensive			Accumulated
	Total			shares		Amount		Capital		Income(Loss)			Deficit
Balance, April 30, 2019	$	2,083,707			5,423,956	$	5,424	$	8,832,590	$	(304	)	$	(6,754,003	)

Net loss for the three months ended July 31, 2019		(450,565	)		-		-		-		-			(450,565	)

Foreign currency translation adjustment		-			-		-		-		-			-

Balance, July 31, 2019	$	1,633,142			5,423,956	$	5,424	$	8,832,590	$	(304	)	$	(7,204,568	)

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six Months Ended
	July 30,
	2019			2018
Cash flows from operating activities:
Net loss	$	(1,023,918	)	$	(2,326,870	)
Adjustments to reconcile net loss to net cash used in operating activities:
Expenses paid on behalf of the Company by related party		-			24,300
Depreciation and amortization		36,094			347
Amortization of right of use asset		9,609			-
Stock-based compensation		252,700			1,763,950
Changes in operating assets and liabilities:
Inventories		-			(50,473	)
Accounts receivable		(57,454	)		263
Prepaid expenses		34,225			95,000
Deferred revenue		-			49,000
Deposit on sales		(71,225	)		-
Operating lease liability		(9,175	)		-
Accounts payable and accrued expenses		318,576			61,541
Net Cash Used In Operating Activities		(510,568	)		(382,942	)

Cash flows from investing activities:
Purchase of equipment		-			(4,163	)
Net Cash Used in Investing Activities		-			(4,163	)

Cash flows from financing activities:
Payment of bank overdraft		-			(762	)
Proceeds from sale of common stock		-			1,000,000
Proceeds from exercise of warrants		-			500,000
Proceeds from notes payable		50,000			25,000
Payment of notes payable		-			(1,820	)
Proceeds from related parties		-			2,500
Payment of related party payables		-			(41,038	)
Net Cash Provided by Financing Activities		50,000			1,483,880

Effect of exchange rate on cash		(252	)		406

Net change in cash		(460,820	)		1,097,181

Cash and cash equivalents - Beginning of period		474,653			-

Cash and cash equivalents - End of period	$	13,833		$	1,097,181

Supplementary information:

Cash paid for:
Interest	$	-		$	-

Income taxes	$	-		$	-

Supplemental disclosure of non-cash investing and financing activities


Common stock to be issued for services	$	-		$	1,763,950

Adoption of ASC 842 Operating lease asset and liability	$	28,827		$	-

Common stock issued for deposit on acquisition	$	-		$	1,850,000

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Six Months Ended July 31, 2019 And 2018

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Organization

Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd., an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.

On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and $400,000, and a royalty payable to the former owner of 4P Therapeutics, of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into the agreement to acquire 4P Therapeutics.

4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company’s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the “FDA”). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its consumer products are not being marketed in the United States.

With the acquisition of 4P Therapeutics, 4P Therapeutics’ drug development business became the Company’s principal business. The Company’s approach is to use generic drugs that are off patent and incorporate them into the Company’s transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical transdermal products.

Reverse Stock Split and Reduction in Authorized Common Stock

On June 25, 2019, the Company effected one-for-four reverse split, pursuant to which each share of common stock became and was converted into 0.25 share of common stock, and the Company decreased its authorized common stock from 100,000,000 shares to 25,000,000 shares. The reverse split became effective in the marketplace on July 24, 2019. All share and per share information in these financial statements retroactively reflect the reverse split.

Going Concern

The Company’s consolidated financial statements for the six months ended July 31, 2019 have been prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities in the normal course of business. The Company did not generate any revenue prior to the quarter ended October 31, 2018. For the six months ended July 31, 2019, the Company generated revenue of $268,503 on which it recorded cost of revenues of $316,753 and a loss from operations of $1,022,773. The Company requires substantial funding to execute its strategic business plan. Successful business operations and its transition to attaining profitability are dependent upon obtaining significant additional financing, generating revenue primarily from its professional services to cover its overhead, developing its products, and obtaining FDA approval to market any product it develops and implementing a marketing program for such products. The Company will not be able to generate any revenue from its proposed transdermal pharmaceutical products without FDA approval. These factors raise substantial doubt about ability of the Company to continue as a going concern.

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Six Months Ended July 31, 2019 And 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The consolidated balance sheet as of July 31, 2019 and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. The consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods pursuant to Rule 8-03 of Regulation S-X, and consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations, changes in stockholders' equity and cash flows for all periods presented have been made. The information for the consolidated balance sheet as of January 31, 2019 was derived from audited financial statements of the Company. The Company’s significant accounting policies are found below. These policies should be read in conjunction with Note 1 in the Company’s audited financial statements for the year ended January 31, 2019.

Principles of Consolidation

The consolidated financial statements of the Company include the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Revenue Recognition

The Company recognized revenue in accordance with Topic 606 “Revenue from Contracts with Customers. Topic 606 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic 606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

Upon adoption, Topic 606 replaced most existing revenue recognition guidance in U.S. GAAP. The adoption of Topic the new revenue recognition standards did not have any impact on its consolidated financial statements since the Company did not recognize any revenue prior to the third quarter of 2018, and all revenue is recognized pursuant to Topic 606.

Revenue Service Types

The following is a description of the Company’s revenue service types, which include professional services and sale of goods:

●

Professional services include contract research and development related services with clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.

●

Sales revenues are derived from the sale of products. To date, sales related to consumer products sold to the Company’s South Korean distributor. Upon receipt of a purchase order, the Company has the order filled and shipped.

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Six Months Ended July 31, 2019 And 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued

Contracts with Customers

A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) the Company determines that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue types, the performance obligation is satisfied at different times. The Company‘s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When the Company performs professional service work, it recognizes revenue when it has the right to invoice the customer for the work completed, which typically occurs on a monthly basis for the work performed during that month.

All revenue recognized in the statement of operations is revenue from contracts with customers.

Disaggregation of Revenues

The Company disaggregates its revenue from contracts with customers by service type and by geographical location. The following tables set forth revenue by service type and by geographical location.

Revenue by service type:

	Three months ended July 31,				Six months ended July 31,
	2019		2018		2019		2018
Sale of goods	$	-	$	-	$	142,450	$	-
Services		74,913		-		126,053		-
Total	$	74,913	$	-	$	268,503	$	-

Revenue by geographic location:

	Three months ended July 31,				Six months ended July 31,
	2019		2018		2019		2018
United States	$	74,913	$	-	$	126,053	$	-
Non-United States		-		-		142,450		-
Total	$	74,913	$	-	$	268,503	$	-

Property, Plant and Equipment

The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 5 years as follows:

Lab equipment			5 years
Furniture, fixtures and equipment			3 years

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Six Months Ended July 31, 2019 And 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued

Intangibles Assets

Intangibles assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisition in 2018 has also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.

Goodwill

Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceed their fair value. The Company does not amortize goodwill in accordance with ASC 350.

Long-lived Assets

Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value.

Earnings per Share

Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of July 31, 2019 and 2018, there were 57,500 and 182,500 common stock equivalents outstanding, respectively, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

Stock-Based Compensation

ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

For the six months ended July 31, 2018, the Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity - Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. As of February 1, 2019, pursuant to ASU 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Six Months Ended July 31, 2019 And 2018

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued

Leases

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.

The Company adopted ASU 2016-02 as amended effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, the Company elected to utilize the Comparative Under 840 Option whereby the Company will continue to present prior period financial statements and disclosures under ASC 840. In addition, the Company elected the transition package of three practical expedients permitted under the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.

Adoption of the new standard resulted in the recording of right-to-use assets in the amount of $28,827 and lease liabilities related to operating leases in the amount of $28,827 on the Company’s consolidated balance sheet as of February 1, 2019. See Note 10, Leases, for Topic 842 disclosures in connection with the adoption of ASU 2016-02.

Recent Accounting Standards

The Company has implemented all new pronouncements, including the adoption of ASC 842 and 718, that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements or results of operations.

3. PROPERTY AND EQUIPMENT

	July 31,			January 31,
	2019			2018
Lab equipment	$	144,585		$	144,585
Furniture, fixtures and equipment		19,643			19,643
		164,228			164,228
Less: Accumulated depreciation		(35,640	)		(18,081	)
Net Property and Equipment	$	128,588		$	146,147

Depreciation expense amounted to $17,559 and $347 for the six months ended July 31, 2019 and 2018, respectively.

4. DEBT

On September 12, 2017, the Company borrowed $15,000 on an interest-free basis from a minority stockholder. In April 2018, the Company borrowed an additional $25,000 from the minority stockholder. In July 2019, the Company borrowed an additional $50,000. The loans are interest free and due upon demand. The balance due on such loans was $90,000 on July 31, 2019, and $40,000 on January 31, 2019, which is included in notes payable.

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Six Months Ended July 31, 2019 And 2018

5. ACQUISITION OF BUSINESS

On August 1, 2018, the Company acquired 100% of the membership interests of 4P Therapeutics, pursuant to an agreement dated April 5, 2018, for $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and $400,000, and a royalty payable to the former owner of 4P Therapeutics, of 6% on all revenue generated by us from the abuse deterrent intellectual property that had been developed by 4P Therapeutics. The primary purpose of the acquisition is to acquire the intellectual property of 4P Therapeutics and complete the development and seek FDA approval on a number of transdermal pharmaceutical products under development by 4P Therapeutics which are in the preclinical stage. As a result of the acquisition of 4P Therapeutics, the Company has a pipeline of potential products. Acquisition costs, which were minimal, have been expensed as incurred in accordance with ASC 350.

Details of the net assets acquired are as follows:

	Fair Value Recognized
	On Acquisition
Equipment	$	160,065
Customer base		136,500
Intellectual property		191,900
Trademark		42,300
Goodwill		1,719,235
Net assets acquired	$	2,250,000
Satisfied by:
Common stock issued	$	(1,850,000	)
Cash outflows on acquisition		(400,000	)

The following unaudited pro forma condensed financial information presents the combined results of operations of the Company and 4P Therapeutics as if the acquisition occurred as of the beginning of six-month period ended July 31, 2018. The unaudited pro forma condensed financial information is not intended to represent or be indicative of the consolidated results of operations of the Company that would have been reported had the acquisition occurred at the beginning of the period presented and should not be taken as being representation of the future consolidated results of operations of the Company.

	Six months ended July 31, 2018
	As Reported			Pro Forma
Revenue	$	-		$	331,864
Net loss	$	(2,326,870	)	$	(2,421,391	)
Loss per share of common stock (basic and diluted)	$	(0.44	)	$	(0.46	)

6. INTANGIBLE ASSETS AND GOODWILL

At July 31, 2019 and January 31, 2019, intangible assets consisted of intellectual property, customer base and trademarks, net of amortization, as follows:

	July 31,			January 31,
	2019			2019
Customer base	$	136,500		$	136,500
Intellectual property		234,200			234,200
Goodwill		1,719,235			1,719,235

Total		2,089,935			2,089,935

Less: Accumulated amortization		(37,465	)		(18,930	)

Net Intangible Assets	$	2,052,470		$	2,071,005

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Six Months Ended July 31, 2019 And 2018

6. INTANGIBLE ASSETS AND GOODWILL, continued

The value of the intangible assets, consisting of intellectual property and customer base has been recorded at their fair value by the Company after completing a valuation and are being amortized over a period of ten years. Amortization expense for the six months ended July 31, 2019 and 2018 was $18,535 and $-0- respectively.

No value has been given to the potential royalty payable to the former owner since the royalty is contingent upon the Company generating revenue from any source and there is no marketable product and there are material uncertainties, including the need for FDA approval, as to whether or when any revenue will be generated from the intellectual property subject to the royalty. If any royalties are paid to the former owner of 4P Therapeutics, the royalties will be expensed as incurred and treated as a cost of revenue.

Intangible assets consist of:

Intellectual property	$	234,200
Accumulated amortization		(23,815	)
Book value at July 31, 2019	$	210,385

Customer base	$	136,500
Accumulated amortization		(13,650	)
Book value at July 31, 2019	$	122,850
Total Intangible Assets, Net	$	333,235

	Trademarks and Intellectual		Customer
Estimated Amortization:	Property		Base		Total
Year Ended January 31,
2020	$	11,710	$	6,825	$	18,535
2021		23,420		13,650		37,070
2022		23,420		13,650		37,070
2023		23,420		13,650		37,070
2024 and thereafter		128,415		75,075		203,490
	$	210,385	$	122,850	$	333,235

7. RELATED PARTY TRANSACTIONS

The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. See Note 4 in connection with the terms of the acquisition of 4P Therapeutics from the former owner. The former owner was not a director of the Company when the acquisition agreement was signed.

During the six months ended July 31, 2018, the Company issued:

(i)

68,000 shares of common stock, valued at $1,419,300, issued to executive officers and their affiliates;

(ii)

7,500 shares of common stock, valued at $222,000, issued to the Company’s independent directors;

(iii)

2,500 shares of common stock, valued at $74,000, issued to the Company’s advisory board member; and

(iv)

2,500 shares of common stock, valued at $48,600, issued to a non-affiliated party for services.

On February 19, 2019, the Company granted an executive officer an option to purchased 25,000 shares of the Company’s common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise. The fair value of the warrant on the date of grant using the Black Scholes model was $252,700 and was expensed during the six months ended July 31, 2019. The warrant expired unexercised on May 19, 2019.

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Six Months Ended July 31, 2019 And 2018

8. COMMON STOCK

During the six months ended July 31, 2018, the Company issued:

(i)

68,000 shares of common stock, valued at $1,419,300, issued to executive officers and their affiliates;

(ii)

7,500 shares of common stock, valued at $222,000, issued to the Company’s independent directors;

(iii)

2,500 shares of common stock, valued at $74,000, issued to the Company’s advisory board member; and

(iv)

2,500 shares of common stock, valued at $48,600, issued to a non-affiliated party for services.

On May 2, 2018, the Company sold to an unrelated party for $1.0 million, 62,500 shares stock and 30-day warrants to purchase 62,500 shares of common stock at $16.00 per share. On May 27, 2018, the unrelated party exercised warrants to purchase 31,250 shares of common stock for proceeds of $500,000 and on June 2, 2018, warrants to purchase 31,250 shares of common stock expired unexercised.

On July 31, 2018, the Company issued 62,500 shares of common stock valued at $1,850,000 representing a portion of the purchase price for the equity of 4P Therapeutics. See Notes 4 and 6.

In November 2018, one of the defendants in the legal proceedings with Advanced Health Brands, Inc., returned 50,000 shares of common stock that had been issued to her, and these shares were cancelled as of January 31, 2019.

On May 24, 2019, the Board of Directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (“Series A Preferred Stock”). On June 20, 2019, the Series A preferred Stock was terminated and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the Board of Directors.

9. WARRANTS AND OPTIONS

The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company’s common stock issued to non-employees of the Company.

				Exercise		Remaining		Intrinsic
	Shares			Price		Life		Value
Outstanding, January 31, 2019		182,500		$	6.32		0.35 years	$	4,101,000

Granted		-			-		-		-

Expired/Cancelled		(125,000	)		2.80		-		-

Exercised		-			-		-		-

Outstanding-period ending July 31, 2019		57,500		$	14.00		0.50 years	$	1,466,250

Exercisable - period ending July 31, 2019		57,500		$	14.00		0.50 years	$	1,466,250

The following table summarizes additional information relating to the warrants outstanding at July 31, 2019:

Range of		Number		Remaining Contractual		Exercise Price for Shares		Number		Exercise Price for Shares
Exercise Prices		Outstanding		Life(Years)		Outstanding		Exercisable		Exercisable

$	14.00		57,500		0.50	$	14.00		57,500	$	14.00

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Six Months Ended July 31, 2019 And 2018

9. WARRANTS AND OPTIONS, continued

The following table summarizes the changes in options outstanding and the related price of the shares of the Company’s common stock issued to non-employees of the Company.

				Exercise		Remaining		Intrinsic
	Shares			Price		Life		Value
Outstanding, January 31, 2019		-		$	-		-	$	-

Granted		25,000			25.64		0.05 years		232,750

Expired/Cancelled		(25,000	)		25.64		-		-

Exercised		-			-		-		-

Outstanding-period ending July 31, 2019		-		$	-		-	$	-

Exercisable - period ending July 31, 2019		-		$	-		-	$	-

10. LEASES

The Company has operating leases for its facilities used for research and development, sales and administration. These leases have remaining lease terms of less than one year. Certain of these leases contain options to extend the term of the lease and certain of these leases contain options to terminate the lease within a specified period of time. The options to extend or terminate a lease are included in the lease term when it is reasonably likely that the Company will elect that option. The Company is not a party to any material sublease arrangements.

The components of lease expense, which are included in cost of revenues and general and administrative expense, based on the underlying uses of the right of use asset, were as follows:

	Six Months Ended
	July 31, 2019
Amortization of right-of-use asset	$	9,609
Interest on lease liability		1,145
Operating lease costs		-
Total Lease Cost	$	10,754

Supplementary cash flow information related to leases are as follows:

	Six Months Ended
	July 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	9,609
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	28,827

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Six Months Ended July 31, 2019 And 2018

10. LEASES, continued

Supplementary balance sheet information related to leases are as follows:

Operating Leases:
Operating lease right-of -use assets	$	19,218
Operating lease liabilities		19,652

Weighted-Average Remaining Lease Term:
Operating leases		1.00

Weighted-Average Discount Rate:
Operating leases		9.24	%

Our discount rate is based on our incremental borrowing rate.

Maturities of lease liabilities were as follows as of July 31, 2019:

	Operating
Year Ending January 31,	Leases
2020-remaining	$	10,320
2021-remaining		10,320
Total undiscounted cash flows		20,640
Less: imputed interest		(988	)
Present value of lease liabilities	$	19,652

11. CONTINGENCIES

On July 27, 2018, the Company commenced an action in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc., Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without Notice and a Motion for Prejudgment Writ of Replevin arising from the Company’s decision to seek to rescind for misrepresentation the agreement by which the Company acquired advanced Health Brans, Inc. for 1,250,000 shares of common stock valued at $2,500,000 and seek return of the shares. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against the defendants. Defendants Kalmar, Murphy, Polly-Murphy, and Baker have filed a Motion to Dismiss our Verified Complaint, Motion to Dissolve Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019, the court in the Advanced Health Brands, Inc. litigation dismissed the Company’s complaint with prejudice, and directed the defendants to assign the Company within 30 days, the six patents never duly transferred to the Company. On February 1, 2019, the Company appealed the court’s order. In November 2018, one of the defendants returned the 50,000 shares that had been issued to her, and these shares were cancelled as of January 31, 2019.

On August 22, 2018, four of the defendants in the Florida action described in the previous paragraph filed a complaint against the Company in the Franklin County, Ohio Court of Common Pleas seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition agreement. The parties have agreed to a stay pending the outcome of the Florida litigation.

On April 29, 2019, the Company filed a securities fraud action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Advanced Health Brands and TD Therapeutic, Inc. In the complaint the Company alleges that in 2017, the defendants fraudulently and deceitfully obtained 1,250,000 shares of common stock by orchestrating a months-long scheme to defraud us. We are seeking the return of the 1,200,000 shares of common stock and monetary damages resulting from the defendants’ fraudulent conduct. The defendants filed a motion to dismiss.

12. SUBSEQUENT EVENTS

On August 14, 2019, the Company borrowed an additional $50,000 from a minority stockholder, bringing the total loans from the minority stockholder to $140,000. See Note 4.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product is our abuse deterrent fentanyl transdermal system which we are developing to provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches. In November 2018, we raised $500,000 from the sale of our common stock, and we have used the proceeds from that sale for working capital, expenses in connection with our proposed public offering and preliminary preclinical development efforts for our abuse deterrent fentanyl transdermal system. We believe that our abuse deterrent technology can also be utilized in transdermal patches to deter the abuse of other drugs and we are exploring follow-on applications. In addition, we are also exploring the development of generic transdermal patches and the application of our transdermal technology for the transdermal delivery of commercially available drugs or biologics that are typically delivered by injection.

Through July 31, 2018, our business was the development of a line of consumer and health products that are delivered through a transdermal patch which we plan to sell internationally. Consumer products are products that are sold over the counter and do not require a prescription. Most of our consumer products require FDA approval for sale in the United States, and we have not sought to obtain, and we do not plan to seek to obtain, FDA approval to market these product in the United States at this time. Presently our efforts with respect to our consumer transdermal products is limited to our distribution agreement with one distributor which is planning to market our consumer products in South Korea upon receipt of regulatory approval. Through July 31, 2019, we generated modest revenue from the sale of our consumer products to our South Korean distributor, which is conducting preliminary marketing activities in South Korea pending obtaining the necessary regulatory approvals necessary to market the products to consumers in South Korea. We did not generate any revenue from this distributor in the quarter ended July 31, 2019. Since our South Korean distributor has not yet obtained the necessary regulatory approval to market our consumer products in South Korea, we do not anticipate generating any significant revenue from this distributor during the balance of the year ending January 31, 2020. We cannot assure you that our South Korean distributor will obtain necessary regulatory approval in South Korea or in any other country in which it has distribution rights or that, if it does obtain the necessary approval, that we will generate any significant revenue from the distributor. Our agreement with this distributor had an initial term which initially expired on April 30, 2019 and was extended to April 30, 2020. The agreement provides for an automatic renewal for an additional three years and for five-year terms thereafter if certain minimum purchases are made.

With our acquisition of 4P Therapeutics on August 1, 2018, our focus changed, and we are seeking to develop and seek FDA approval on a number of transdermal pharmaceutical products under development by 4P Therapeutics. As a result of the acquisition of 4P Therapeutics, we have a pipeline of potential products.

4P Therapeutics has not generated any revenue from any of its products under development. Rather, prior to our acquisition, 4P Therapeutics generated revenue to provide cash for its operations through contract research and development and related services for a small number of clients in the life sciences field on an as-needed basis. We are, for the near term, continuing this activity, although we do not anticipate that it will generate significant revenues or gross margin. Currently, there are no long-term contractual obligations for us, and either party can terminate at any time. During the six months ended July 31, 2019, we experienced a significant decline in revenue from 4P Therapeutics’ largest customer, as a result of which our revenue from 4P Therapeutics was $126,053. Our revenue from our South Korean distributor for the six months ended July 31, 2019 was $143,450, all of which was generated in the three months ended April 30, 2019. Our cost of revenue for the six months ended July 31, 2019 was $316,753. Our cost of revenue includes fixed expenses, such as the compensation for Dr. Alan Smith, who is our chief operating officer and president of 4P Therapeutics, and the rent for 4P Therapeutics’ facilities. As a result, if we cannot generate sufficient revenue to cover the fixed expenses of 4P Therapeutics, we will continue to generate a negative gross margin from these operations.

With the change in our focus, our capital requirement have increased substantially. The process of developing pharmaceutical products and submitting them for FDA approval is both time consuming and expensive, with no assurance of obtaining approval from the FDA to market our product in the United States. We have budgeted $5.0 million for research and development of our abuse deterrent fentanyl transdermal system, including clinical manufacturing and clinical trials that need to be completed in order to obtain FDA approval. However, the total cost could be substantially in excess of that amount. We do not presently have the funds to enable us to develop our lead product, and we are seeking funding from a proposed public offering for this purpose. We have filed a registration statement with respect to a proposed public offering. Even if we complete the offering, the net proceeds of the offering will not be sufficient for us to complete the development and clinical testing necessary for FDA approval for our lead product. In the event that we are not able to complete the offering, we may be unable to raise the funds necessary to develop our lead product.

In the event that we are not able to complete our proposed public offering, we cannot assure you that we will be able to raise the funds to finance our operations, either through a private placement or a joint venture agreement or strategic relationship, and, if we cannot raise funds as required, we may not be able to fund the development of our product pipeline. Any money we raise in either the proposed public offering or private placement will most likely be at a discount to the then current market price and the discount could be significant, which would result in significant dilution to our stockholders with no assurance any proceeds we raise will be sufficient for us to complete the development of our lead product.

Results of Operations

Three and Six Months Ended July 31, 2019 and 2018

We did not generate revenues during the three months ended July 31, 2018. For the three months ended July 31, 2019, we generated revenue of $74,913 and our costs of revenues were $117,959 resulting in negative gross profit of $43,046. Our revenue was derived from the continuation of research and development contracts of the type that 4P Therapeutics performed prior to our acquisition. There were no sales of transdermal products during the second quarter. Our cost of revenue for our research and development contract in both the three and six month periods includes fixed expenses, such as the compensation for Dr. Alan Smith, who is our chief operating officer and president of 4P Therapeutics, and the rent for 4P Therapeutics’ facilities. As a result, if we cannot generate sufficient revenue to cover the fixed expenses of 4P Therapeutics, we will continue to generate a negative gross margin from these operations.

For the three months ended July 31, 2019, our selling, general and administrative expenses were $406,566, primarily legal, accounting and payroll expense, compared to $1,876,772 in the three months ended July 31, 2018. The decrease from 2018 is primarily due to a decrease in payroll related expenses offset by an increase in legal during the quarter. We had no stock-based compensation for the three months ended July 31, 2019 as compared stock-based compensation of $1,486,450 for the three months ended July 31, 2018.

We incurred interest expense of $953 for the three months ended July 31, 2019. We had no interest expense in the three months ended July 31, 2018.

As a result of the foregoing, we sustained a net loss of $450,565, or $(0.08) per share (basic and diluted), for the three months ended July 31, 2019, as compared with a loss of $1,876,772, or $(0.36) per share (basic and diluted), for the three months ended July 31, 2018.

We did not generate any revenues during the six months ended July 31, 2018. For the six months ended July 31, 2019, we generated revenue of $268,503 and our costs of revenues were $316,753, resulting in negative gross profit of $48,250. Our revenue was derived from two sources – a continuation of research and development contracts of the type that 4P Therapeutics performed prior to our acquisition, which accounted for $126,053, and sales of our consumer transdermal product to our South Korean distributor, which accounted for $142,450, which were generated during the quarter ended April 30, 2019. The sales related to purchases by our South Korean distributor for its preliminary marketing efforts since the product has not obtained regulatory approval for retail sales. We anticipate that all of our revenue for the quarter ended October 31, 2019 will be generated from research and development contracts. Our cost of revenue was $225,285 for our research and development contracts and $91,468 for the consumer patches. Since we do not have the funds for the development of our lead product, the 4P Therapeutics fixed costs are allocated to the contract services that we perform for clients.

For the six months ended July 31, 2019 our selling, general and administrative expenses were $974,523, primarily legal, accounting and payroll expense, compared to $2,326,870 in the six months ended July 31, 2018. The decrease from 2018 is primarily due to a decrease in payroll related expenses offset by an increase in legal fees during the six months. Stock-based compensation was $252,700 for the six months ended July 31, 2019 and $1,763,950 for the six months ended July 31, 2018.

We incurred interest expense of $1,145 for the six months ended July 31, 2019. We had no interest expense in the six months ended July 31, 2018.

As a result of the foregoing, we sustained a net loss of $1,023,918, or $(0.19) per share (basic and diluted) for the six months ended July 31, 2019, compared with a loss of $2,326,870, or $(0.44) per share (basic and diluted) for the six months ended July 31, 2018.

Liquidity and Capital Resources

As of July 31, 2019, we had $13,833 in cash and cash equivalents and a working capital deficiency of $567,134, as compared with cash and cash equivalents of $474,653 and working capital of $187,460 at January 31, 2019.

For the six months ended July 31, 2019, we used cash of $510,568 in our operations. The principal adjustments to our net loss of $1,023,918 were stock-based compensation of $252,700, an increase in accounts payable and accrued expenses of $318,576, a decrease in prepaid expenses of $34,225, depreciation and amortization of $36,094 offset by an increase in accounts receivable of $57,454 and a decrease in customer deposits of $71,225.

For the six months ended July 31, 2018, we used $382,942 in our operations. The principal adjustments to our net loss of $2,326,870, were stock-based compensation of $1,763,950, an increase is accounts payable and accrued expenses of $61,541, a decrease in prepaid expenses of $95,000 and expenses paid by a related party of $24,300. During the six months ended July 31, 2018, our only business was our consumer patches.

For the six months ended July 31, 2019, we had no cash flow from investing activities. For the six months ended July 31, 2018, we used $4,163 in investing activities, representing the purchase of equipment

Our cash flow from financing activities in the six months ended July 31, 2019 consisted of $50,000 from the issuance of notes. For the six months ended July 31, 2018, we had cash flow from financing activities of $1,483,880, consisting of $1,000,000 from the sale of common stock, $500,000 from the exercise of warrants, $25,000 from the issuance of notes, $2,500 from an advance from related parties, offset by $41,038 in payment of related party payables and $1,820 in payment of notes payable.

Off Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies

Going Concern

Our consolidated financial statements for the six months ended July 31, 2019 have been prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities in the normal course of business. We did not generate any revenue prior to the quarter ended October 31, 2018. For the six months ended July 31, 2019, we generated revenue of $268,503 on which we recorded a negative gross profit of $48,250 and a loss from operations of $1,022,773. During the six months ended July 31, 2019, our 4P Therapeutics subsidiary generated revenues of $126,053 and cost of revenues of $225,285 resulting from a significant decrease in sales from the division’s major customer with the result that the revenue was insufficient to cover the fixed costs that are included in cost of revenue. Further, the revenue from the sales of consumer products reflects sales to our South Korean distributor, for its preliminary marketing efforts, and until it has obtained regulatory clearance to sell the products at retail, we do not anticipate generating significant revenues from our South Korean distributor, which is our only distributor. We require substantial funding to execute our strategic business plan. Successful business operations and our transition to attaining profitability are dependent upon obtaining significant additional financing, generating revenue primarily from our professional services to cover our overhead, developing our products, and obtaining FDA approval to market any product we develop and implementing a marketing program for such products. We will not be able to generate any revenue from our proposed transdermal pharmaceutical products without FDA approval. These factors raise substantial doubt about our ability to continue as a going concern.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Revenue Recognition

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. We adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018. Topic 606 requires us to recognize revenues when control of the promised goods or services and receipt of payment is probable. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

Revenue Service Types

The following is a description of our revenue service types, which include professional services and sales of goods:

●

Professional services include the contract of research and development related services with our clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.

●

Sales revenues are generated from the sale of our products. Upon the receipt of a purchase order, we have the order filled and shipped.

Contracts with Customers

A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. Our performance obligations include providing products and professional services in the area of research. We recognize product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs on a monthly basis for work performed during that month.

All revenue recognized in the statement of operations is considered to be revenue from contracts with customers.

Intangible Assets

Intangible assets include intellectual property and other customer base acquired through business combinations. We account for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” We capitalize certain costs related to patent technology, as a substantial portion of the purchase price related to our acquisition has been assigned to the intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Intellectual property and customer base are being amortized over their useful lives of ten years.

Goodwill

Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceed their fair value. In accordance with ASC 350, we do not amortize goodwill.

Long-lived Assets

Stock-Based Compensation

ASC 718, “Compensation — Stock Compensation,” prescribes accounting and reporting standards for all stock-based payment transactions in which employee services, and, since February 1, 2019, non-employee services, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Stock-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

For the six months ended July 31, 2018, we account for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity — Based Payments to Non-Employees.” Measurement of stock-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

Leases

We adopted ASU 2016-02 as amended effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, we elected to utilize the Comparative Under 840 Option whereby we will continue to present prior period financial statements and disclosures under ASC 840. In addition, we elected the transition package of three practical expedients permitted under the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. We completed the necessary changes to our accounting policies, processes, disclosure and internal control over financial reporting.

Foreign Currency Translation

The functional currency of our Irish subsidiary is the Euro. The assets and liabilities of the subsidiary are translated into US dollars using the prevailing exchange rate as of the balance sheet date and income and expenses are translated into US dollars using the average exchange rate during the reporting period. Translation adjustments are recorded in other comprehensive (loss).

Business Combinations

Business combinations are accounted for using the acquisition method in accordance with ASC Topic 805, Business Combinations (“ASC 805”). Under the acquisition method of accounting, we allocate the purchase price of a business acquisition based on the fair value of the identifiable tangible and intangible assets. The difference between the total cost of the acquisition and the sum of the fair values of the acquired tangible and identifiable intangible assets less liabilities is recorded as goodwill or bargain purchase gain. Under ASC 805, acquisition related transaction costs (such as advisory, legal, valuation, and other professional fees) are expensed as incurred.

New Financial Accounting Standards

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the consolidated financial statements included herewith.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures.

As of the end of period covered by this report, we carried out an evaluation, with the participation of our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures pursuant to Securities Exchange Act Rule 13a-15. Based upon that evaluation, we concluded that for reasons discussed in our annual report on Form 10-K for the year ended January 31, 2019, our disclosure controls and procedures are not effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

As reported in our Form 10-K, management has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel, excessive reliance on third party consultants for accounting, financial reporting and related activities, and the lack of any separation of duties. Because of our financial condition it is unlikely that we will be able to implement effective internal controls over financial reporting in the near future.

Until we generate significantly greater revenues and employ accounting personnel, it is doubtful that we will be able implement any system which provides us with any degree of internal controls over financial reporting. Due to the nature of this material weakness in our internal control over financial reporting, there is more than a remote likelihood that misstatements which could be material to our annual or interim financial statements could not be prevented or detected.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

Changes in Internal Control over Financial Reporting

No changes were made to our internal controls in the quarterly period covered by this report that have materially affected, or are reasonably likely materially to affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 5. OTHER INFORMATION.

On April 23, 2019, we entered into employment agreements with Gareth Sheridan and Sergei Melnik pursuant to which we agree to employ Mr. Sheridan as chief executive officer and Mr. Melnik as chief financial officer. The agreements also provide that we will include each of them as our nominee for director. The agreements have a term ending on January 31, 2024, and continue on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension, Pursuant to the employment agreements, Mr. Sheridan is currently receiving compensation at the annual rate of $42,000, and Mr. Melnik is not currently receiving any compensation. Commencing with the month in which we have raised at least $2,500,000 from the public or private financing of our equity securities, they will each receive salary at the annual rate of $170,000.

ITEM 6. EXHIBITS.

Exhibits

Exhibit Number		Description of Exhibits
31.1		Section 302 Certificate of Chief Executive Officer.
31.2		Section 302 Certification of Chief Financial Officer
32.1		Section 906 Certificate of Chief Executive Officer and Principal Financial Officer.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Schema Document
101.CAL		XBRL Taxonomy Calculation Linkbase Document
101.DEF		XBRL Taxonomy Definition Linkbase Document
101.LAB		XBRL Taxonomy Label Linkbase Document
101.PRE		XBRL Taxonomy Presentation Linkbase Document

SIGNATURES

In accordance with the requirements of the Exchange Act, the Company has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NUTRIBAND INC.
September 12, 2019
	By:	/s/ Gareth Sheridan
		Gareth Sheridan, Chief Executive Officer
		(Principal Executive Officer)

September 12, 2019
	By:	/s/ Serguei Melnik
		Serguei Melnik, Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 f10q0719ex31-1_nutriband.htm CERTIFICATION

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Gareth Sheridan, certify that:

I have reviewed this quarterly report on Form 10-Q of Nutriband Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
	b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

DATE: September 12, 2019	/s/ Gareth Sheridan
	Gareth Sheridan, Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 f10q0719ex31-2_nutriband.htm CERTIFICATION

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Serguei Melnik, certify that:

I have reviewed this quarterly report on Form 10-Q of Nutriband Inc.;

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

DATE: September 12, 2019	/s/ Serguei Melnik
	Serguei Melnik, Chief Financial Officer
	(Principal Financial Officer)

EX-32.1 4 f10q0719ex32-1_nutriband.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Nutriband Inc. (the “Company”) on Form 10-Q for the quarter ended July 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Gareth Sheridan, chief executive officer, and I, Serguei Melnik, chief financial officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

September 12, 2019
	/s/ Gareth Sheridan
	Gareth Sheridan, Chief Executive Officer
	(Principal Executive Officer)
September 12, 2019
	/s/ Serguei Melnik
	Serguei Melnik, Chief Financial Officer
	(Principal Financial Officer)

EX-101.INS 5 ntrb-20190731.xml XBRL INSTANCE FILE 0001676047 2019-02-01 2019-07-31 0001676047 2018-01-31 0001676047 2019-07-31 0001676047 2018-02-01 2018-07-31 0001676047 us-gaap:WarrantMember 2019-07-31 0001676047 us-gaap:WarrantMember 2019-02-01 2019-07-31 0001676047 us-gaap:CommonStockMember 2019-02-01 2019-07-31 0001676047 us-gaap:CommonStockMember 2018-04-26 2018-05-02 0001676047 us-gaap:CommonStockMember 2018-05-20 2018-05-27 0001676047 us-gaap:EquipmentMember 2019-02-01 2019-07-31 0001676047 srt:MaximumMember 2019-02-01 2019-07-31 0001676047 srt:MinimumMember 2019-02-01 2019-07-31 0001676047 2018-07-31 0001676047 us-gaap:CommonStockMember 2018-02-01 2018-07-31 0001676047 us-gaap:CommonStockMember 2018-01-31 0001676047 us-gaap:CommonStockMember 2019-07-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2018-02-01 2018-07-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2019-02-01 2019-07-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2018-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2019-07-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-02-01 2018-07-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-02-01 2019-07-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-31 0001676047 us-gaap:RetainedEarningsMember 2018-02-01 2018-07-31 0001676047 us-gaap:RetainedEarningsMember 2019-02-01 2019-07-31 0001676047 us-gaap:RetainedEarningsMember 2018-01-31 0001676047 us-gaap:RetainedEarningsMember 2019-07-31 0001676047 us-gaap:FurnitureAndFixturesMember 2019-02-01 2019-07-31 0001676047 us-gaap:NonUsMember 2019-02-01 2019-07-31 0001676047 us-gaap:NonUsMember 2018-02-01 2018-07-31 0001676047 country:US 2019-02-01 2019-07-31 0001676047 country:US 2018-02-01 2018-07-31 0001676047 us-gaap:EquipmentMember 2019-07-31 0001676047 us-gaap:EquipmentMember 2018-01-31 0001676047 us-gaap:FurnitureAndFixturesMember 2019-07-31 0001676047 us-gaap:FurnitureAndFixturesMember 2018-01-31 0001676047 us-gaap:CommonStockMember ntrb:AdvancedHealthBrandsMember 2018-11-30 0001676047 us-gaap:CommonStockMember ntrb:AdvancedHealthBrandsMember 2018-11-01 2018-11-30 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember 2019-02-01 2019-07-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember 2019-07-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:CustomerRelatedIntangibleAssetsMember 2019-07-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:IntellectualPropertyMember 2019-07-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:GoodwillMember 2019-07-31 0001676047 us-gaap:CustomerRelatedIntangibleAssetsMember 2019-07-31 0001676047 2018-07-01 2018-07-27 0001676047 2019-01-31 0001676047 2018-04-30 0001676047 ntrb:LeasesMember 2019-02-02 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:CustomerRelatedIntangibleAssetsMember 2019-01-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:IntellectualPropertyMember 2019-01-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:GoodwillMember 2019-01-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember 2019-01-31 0001676047 ntrb:TrademarkAndIntellectualPropertyMember 2019-07-31 0001676047 us-gaap:WarrantMember 2019-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2019-02-01 2019-07-31 0001676047 us-gaap:EmployeeStockOptionMember 2019-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2019-07-31 0001676047 ntrb:DefendantsMember 2019-01-21 2019-01-31 0001676047 ntrb:CommonStockToBeIssuedMember 2018-07-31 0001676047 us-gaap:CommonStockMember 2019-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2018-07-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-31 0001676047 us-gaap:RetainedEarningsMember 2018-07-31 0001676047 us-gaap:RetainedEarningsMember 2019-01-31 0001676047 us-gaap:CommonStockMember 2018-07-31 0001676047 2018-07-25 2018-08-01 0001676047 2018-07-26 2018-08-01 0001676047 2018-08-01 0001676047 ntrb:FourPTherapeuticsLlcMember 2018-08-01 0001676047 srt:ExecutiveOfficerMember 2018-02-01 2018-07-31 0001676047 srt:ChiefExecutiveOfficerMember 2019-02-05 2019-02-19 0001676047 us-gaap:CommonStockMember 2018-05-11 2018-06-02 0001676047 2019-06-01 2019-06-25 0001676047 2019-05-01 2019-07-31 0001676047 2018-05-01 2018-07-31 0001676047 us-gaap:NonUsMember 2019-05-01 2019-07-31 0001676047 us-gaap:NonUsMember 2018-05-01 2018-07-31 0001676047 country:US 2019-05-01 2019-07-31 0001676047 country:US 2018-05-01 2018-07-31 0001676047 ntrb:MinorityStockholderMember 2017-09-12 0001676047 ntrb:MinorityStockholderMember 2018-04-30 0001676047 ntrb:MinorityStockholderMember 2019-07-31 0001676047 ntrb:HealthBransIncMember 2019-04-24 2019-04-29 0001676047 us-gaap:CommonStockMember 2019-05-01 2019-07-31 0001676047 us-gaap:CommonStockMember 2018-05-01 2018-07-31 0001676047 us-gaap:CommonStockMember 2019-04-30 0001676047 us-gaap:CommonStockMember 2018-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2019-05-01 2019-07-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2018-05-01 2018-07-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2019-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2018-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-05-01 2019-07-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-05-01 2018-07-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-30 0001676047 us-gaap:RetainedEarningsMember 2019-05-01 2019-07-31 0001676047 us-gaap:RetainedEarningsMember 2018-05-01 2018-07-31 0001676047 us-gaap:RetainedEarningsMember 2019-04-30 0001676047 us-gaap:RetainedEarningsMember 2018-04-30 0001676047 ntrb:CommonStockToBeIssuedMember 2018-05-01 2018-07-31 0001676047 ntrb:CommonStockToBeIssuedMember 2018-04-30 0001676047 2019-04-30 0001676047 srt:DirectorMember 2018-02-01 2018-07-31 0001676047 ntrb:AdvisoryBoardMember 2018-02-01 2018-07-31 0001676047 ntrb:NonAffiliatedMember 2018-02-01 2018-07-31 0001676047 us-gaap:SeriesAPreferredStockMember 2019-05-01 2019-05-24 0001676047 us-gaap:SeriesAPreferredStockMember 2019-06-01 2019-06-20 0001676047 2019-08-14 0001676047 ntrb:FourPTherapeuticsLlcMember 2018-04-03 2018-04-05 0001676047 ntrb:FourPTherapeuticsLlcMember 2018-04-05 0001676047 ntrb:RangeOfExercisePricesThreeMember 2019-07-31 0001676047 ntrb:RangeOfExercisePricesThreeMember 2019-02-01 2019-07-31 0001676047 2019-09-11 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure Nutriband Inc. 0001676047 false --01-31 10-Q 2019-07-31 2020 Non-accelerated Filer

0.001

10000000

0.001

5423956

50000

5423956

268503

142450

126053

74913

62500

68000

62500

7500

2500

62500

1250000

62500

1850000

1849937

2500000

1850000

1849937

true

57500

182500

57500

true

1719235

316753

P5Y

P3Y

142450 126053 74913

90000

40000

146147

128588

144585

19643

146147

333235

122850

351770

210385

Q2 true

19652

28827

19218

28827

2500000

6. INTANGIBLE ASSETS AND GOODWILL   At July 31, 2019 and January 31, 2019, intangible assets consisted of intellectual property, customer base and trademarks, net of amortization, as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">July 31,</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">January 31,</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Customer base</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">136,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">136,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">234,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">234,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,719,235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,719,235</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,089,935</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,089,935</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(37,465</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(18,930</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net Intangible Assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,052,470</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,071,005</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>    The value of the intangible assets, consisting of intellectual property and customer base has been recorded at their fair value by the Company after completing a valuation and are being amortized over a period of ten years. Amortization expense for the six months ended July 31, 2019 and 2018 was $18,535 and $-0- respectively.   No value has been given to the potential royalty payable to the former owner since the royalty is contingent upon the Company generating revenue from any source and there is no marketable product and there are material uncertainties, including the need for FDA approval, as to whether or when any revenue will be generated from the intellectual property subject to the royalty. If any royalties are paid to the former owner of 4P Therapeutics, the royalties will be expensed as incurred and treated as a cost of revenue.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible assets consist of:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Intellectual property</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">234,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,815</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Book value at July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">210,385</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer base</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">136,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,650</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Book value at July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">122,850</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Total Intangible Assets, Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">333,235</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"></td><td> </td> <td colspan="2" style="text-align: center">Trademarks and Intellectual</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Customer</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Estimated Amortization:</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> Property</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Base</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Year Ended January 31,</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,710</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,825</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,535</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,070</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,070</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,070</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2024 and thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">128,415</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,075</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">203,490</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">210,385</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">122,850</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">333,235</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

121508

1633142

2908986

5219

5424

2966145

8832590

-446

-304

-2849410

-7204568

2404612

-48944

5424

8079858

8579890

-48

-52

-5176280

-6180650

5456

5424

5219

8832590

2966145

-304

-300

-6754003

-3297508

277500

2083707

5219275

5423956

5456025

5423956

5219275

1763950

1850000

1763870

1486450

1763870

-277500

-1023918

-2326870

-1023918

-450565

-1878772

-450565

-1878772

-252

398

-252

252

-1850000

400000

160065

136500

191900

42300

2250000

1.00

1000000

999937

1419300

1000000

999937

222000

74000

48600

252700 252700

62500

80500

Yes 5423956 000-55654 No NV

The Company effected one-for-four reverse split, pursuant to which each share of common stock became and was converted into 0.25 share of common stock, and the Company decreased its authorized common stock from 100,000,000 shares to 25,000,000 shares. The reverse split became effective in the marketplace on July 24, 2019. All share and per share information in these financial statements retroactively reflect the reverse split.

P10Y

164228

18081

35640

17559

347

15000

25000

50000

331864

-2421391

-0.46

5. ACQUISITION OF BUSINESS   On August 1, 2018, the Company acquired 100% of the membership interests of 4P Therapeutics, pursuant to an agreement dated April 5, 2018, for $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and $400,000, and a royalty payable to the former owner of 4P Therapeutics, of 6% on all revenue generated by us from the abuse deterrent intellectual property that had been developed by 4P Therapeutics. The primary purpose of the acquisition is to acquire the intellectual property of 4P Therapeutics and complete the development and seek FDA approval on a number of transdermal pharmaceutical products under development by 4P Therapeutics which are in the preclinical stage. As a result of the acquisition of 4P Therapeutics, the Company has a pipeline of potential products. Acquisition costs, which were minimal, have been expensed as incurred in accordance with ASC 350.   Details of the net assets acquired are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Fair Value Recognized</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">On Acquisition</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">160,065</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer base</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">191,900</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trademark</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,719,235</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Net assets acquired</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,250,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Satisfied by:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Common stock issued</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,850,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash outflows on acquisition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(400,000</td><td style="text-align: left">)</td></tr> </table>   The following unaudited pro forma condensed financial information presents the combined results of operations of the Company and 4P Therapeutics as if the acquisition occurred as of the beginning of six-month period ended July 31, 2018. The unaudited pro forma condensed financial information is not intended to represent or be indicative of the consolidated results of operations of the Company that would have been reported had the acquisition occurred at the beginning of the period presented and should not be taken as being representation of the future consolidated results of operations of the Company.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended July 31, 2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">As Reported</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Pro Forma</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding: 0; text-indent: 0">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">331,864</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding: 0; text-indent: 0">Net loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,326,870</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,421,391</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding: 0; text-indent: 0">Loss per share of common stock (basic and diluted)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.44</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.46</td><td style="text-align: left">)</td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Fair Value Recognized</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">On Acquisition</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">160,065</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer base</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">191,900</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trademark</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,719,235</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Net assets acquired</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,250,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Satisfied by:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Common stock issued</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,850,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash outflows on acquisition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(400,000</td><td style="text-align: left">)</td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended July 31, 2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">As Reported</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Pro Forma</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding: 0; text-indent: 0">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">331,864</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding: 0; text-indent: 0">Net loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,326,870</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,421,391</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding: 0; text-indent: 0">Loss per share of common stock (basic and diluted)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.44</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.46</td><td style="text-align: left">)</td></tr></table> 9. WARRANTS AND OPTIONS   The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company's common stock issued to non-employees of the Company.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Life</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">182,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> 0.35 years </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired/Cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(125,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding-period ending July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">57,500</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"> 0.50 years </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,466,250</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable - period ending July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">57,500</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"> 0.50 years </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,466,250</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   The following table summarizes additional information relating to the warrants outstanding at July 31, 2019:    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center">Range of</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Number</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Remaining Contractual</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Exercise Price for Shares</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Number</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Exercise Price for Shares</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> Exercise Prices</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Life(Years)</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> Outstanding</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> Exercisable</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left"> </td></tr> </table>   The following table summarizes the changes in options outstanding and the related price of the shares of the Company's common stock issued to non-employees of the Company.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Life</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, January 31, 2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Granted</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">25.64</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> 0.05 years </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">232,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired/Cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding-period ending July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable - period ending July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center">Range of</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Number</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Remaining Contractual</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Exercise Price for Shares</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Number</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Exercise Price for Shares</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> Exercise Prices</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Life(Years)</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> Outstanding</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> Exercisable</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14.00</td><td style="text-align: left"> </td></tr></table>

25000

31250

14.00

6.32

25.64

2.80

25.64

14.00

P0Y4M6D

P0Y6M0D

1466250

4101000

1466250

P0Y0M18D

9609

1145

10754

9609 28827

19652

P1Y

0.0924

10320

20640

19652

988

11. CONTINGENCIES   On July 27, 2018, the Company commenced an action in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc., Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without Notice and a Motion for Prejudgment Writ of Replevin arising from the Company's decision to seek to rescind for misrepresentation the agreement by which the Company acquired advanced Health Brans, Inc. for 1,250,000 shares of common stock valued at $2,500,000 and seek return of the shares. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against the defendants. Defendants Kalmar, Murphy, Polly-Murphy, and Baker have filed a Motion to Dismiss our Verified Complaint, Motion to Dissolve Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019, the court in the Advanced Health Brands, Inc. litigation dismissed the Company's complaint with prejudice, and directed the defendants to assign the Company within 30 days, the six patents never duly transferred to the Company. On February 1, 2019, the Company appealed the court's order. In November 2018, one of the defendants returned the 50,000 shares that had been issued to her, and these shares were cancelled as of January 31, 2019.   On August 22, 2018, four of the defendants in the Florida action described in the previous paragraph filed a complaint against the Company in the Franklin County, Ohio Court of Common Pleas seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition agreement. The parties have agreed to a stay pending the outcome of the Florida litigation.   On April 29, 2019, the Company filed a securities fraud action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Advanced Health Brands and TD Therapeutic, Inc. In the complaint the Company alleges that in 2017, the defendants fraudulently and deceitfully obtained 1,250,000 shares of common stock by orchestrating a months-long scheme to defraud us. We are seeking the return of the 1,200,000 shares of common stock and monetary damages resulting from the defendants' fraudulent conduct. The defendants filed a motion to dismiss.

1200000

50000

2353151

2807618

-7204568

-6180650

-304

-52

8832590

8579890

5424

720009

403006

90000

40000

71225

610357

291781

2353151

2807618

152875

590466

68500

102725

70542

13088

25000000

5423956

500000

499969

500000

499969

7. RELATED PARTY TRANSACTIONS   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in; text-align: left">a)</td><td style="text-align: justify">The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. See Note 4 in connection with the terms of the acquisition of 4P Therapeutics from the former owner. The former owner was not a director of the Company when the acquisition agreement was signed.</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in; text-align: left">b)</td><td>During the six months ended July 31, 2018, the Company issued:</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(i)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">68,000 shares of common stock, valued at $1,419,300, issued to executive officers and their affiliates;</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(ii)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">7,500 shares of common stock, valued at $222,000, issued to the Company's independent directors;</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(iii)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">2,500 shares of common stock, valued at $74,000, issued to the Company's advisory board member; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(iv)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">2,500 shares of common stock, valued at $48,600, issued to a non-affiliated party for services.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">c)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">On February 19, 2019, the Company granted an executive officer an option to purchased 25,000 shares of the Company's common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise. The fair value of the warrant on the date of grant using the Black Scholes model was $252,700 and was expensed during the six months ended July 31, 2019. The warrant expired unexercised on May 19, 2019.</td></tr></table>

8. COMMON STOCK   During the six months ended July 31, 2018, the Company issued:   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">68,000 shares of common stock, valued at $1,419,300, issued to executive officers and their affiliates;</td> </tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify">7,500 shares of common stock, valued at $222,000, issued to the Company's independent directors;</td> </tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify">2,500 shares of common stock, valued at $74,000, issued to the Company's advisory board member; and</td> </tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(iv)</td><td style="text-align: justify">2,500 shares of common stock, valued at $48,600, issued to a non-affiliated party for services.</td> </tr></table>   On May 2, 2018, the Company sold to an unrelated party for $1.0 million, 62,500 shares stock and 30-day warrants to purchase 62,500 shares of common stock at $16.00 per share. On May 27, 2018, the unrelated party exercised warrants to purchase 31,250 shares of common stock for proceeds of $500,000 and on June 2, 2018, warrants to purchase 31,250 shares of common stock expired unexercised.   On July 31, 2018, the Company issued 62,500 shares of common stock valued at $1,850,000 representing a portion of the purchase price for the equity of 4P Therapeutics. See Notes 4 and 6.   In November 2018, one of the defendants in the legal proceedings with Advanced Health Brands, Inc., returned 50,000 shares of common stock that had been issued to her, and these shares were cancelled as of January 31, 2019.   On May 24, 2019, the Board of Directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock ("Series A Preferred Stock"). On June 20, 2019, the Series A preferred Stock was terminated and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the Board of Directors.

12. SUBSEQUENT EVENTS   On August 14, 2019, the Company borrowed an additional $50,000 from a minority stockholder, bringing the total loans from the minority stockholder to $140,000. See Note 4.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">July 31,</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">January 31,</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Customer base</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">136,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">136,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">234,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">234,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,719,235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,719,235</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,089,935</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,089,935</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(37,465</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(18,930</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net Intangible Assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,052,470</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,071,005</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible assets consist of:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Intellectual property</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">234,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,815</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Book value at July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">210,385</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer base</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">136,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,650</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Book value at July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">122,850</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Total Intangible Assets, Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">333,235</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>

2089935

136500

234200

1719235

136500

234200

1719235

2089935

-37465

-18930

2052470

2071005

234200 -23815 210385 136500 -13650 122850

18535

6825

11710

37070

13650

23420

37070

13650

23420

37070

13650

23420

203490

75075

128415

18535 0

The Company granted an executive officer an option to purchased 25,000 shares of the Company's common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise. The fair value of the warrant on the date of grant using the Black Scholes model was $252,700 and was expensed during the six months ended July 31, 2019. The warrant expired unexercised on May 19, 2019.

1000000

62500 P30D 16.00 500000 31250 31250 2019-01-31

140000

50000

316753 117959

974523

2326870

406566

1878772

1291276

2326870

524525

1878772

-1022773

-2326870

-449612

-1878772

1145

953

-1023918

-2326870

-450565

-1878772

-0.19

-0.44

-0.08

-0.36

5423956

5265406

5423956

5310033

-1023918

-2326870

-573353

-1878772

-252

398

252

-1024170

-2326472

-573353

-1878520

24300

36094

347

9609

252700

1763950

50473

57454

-263

-34225

-95000

49000

-71225

-9175

318576

61541

-510568

-382942

4163

-4163

-762

1000000

500000

50000

25000

1820

2500

41038

50000

1483880

-252

406

-460820

1097181

13833

1097181

474653

1763950 28827 1850000

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   The consolidated balance sheet as of July 31, 2019 and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. The consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods pursuant to Rule 8-03 of Regulation S-X, and consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations, changes in stockholders' equity and cash flows for all periods presented have been made. The information for the consolidated balance sheet as of January 31, 2019 was derived from audited financial statements of the Company. The Company’s significant accounting policies are found below. These policies should be read in conjunction with Note 1 in the Company’s audited financial statements for the year ended January 31, 2019.   Principles of Consolidation   The consolidated financial statements of the Company include the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018.   Use of Estimates   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities.  On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances.  The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  Actual results could differ from those estimates.   Revenue Recognition   The Company recognized revenue in accordance with Topic 606 “Revenue from Contracts with Customers. Topic 606 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic 606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.   Upon adoption, Topic 606 replaced most existing revenue recognition guidance in U.S. GAAP. The adoption of Topic the new revenue recognition standards did not have any impact on its consolidated financial statements since the Company did not recognize any revenue prior to the third quarter of 2018, and all revenue is recognized pursuant to Topic 606.   Revenue Service Types   The following is a description of the Company’s revenue service types, which include professional services and sale of goods:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Professional services include contract research and development related services with clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Sales revenues are derived from the sale of products. To date, sales related to consumer products sold to the Company’s South Korean distributor. Upon receipt of a purchase order, the Company has the order filled and shipped.</td> </tr></table>    Contracts with Customers   A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) the Company determines that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.   Performance Obligations   A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue types, the performance obligation is satisfied at different times. The Company‘s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When the Company performs professional service work, it recognizes revenue when it has the right to invoice the customer for the work completed, which typically occurs on a monthly basis for the work performed during that month.   All revenue recognized in the statement of operations is revenue from contracts with customers.   Disaggregation of Revenues   The Company disaggregates its revenue from contracts with customers by service type and by geographical location. The following tables set forth revenue by service type and by geographical location.   Revenue by service type:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Three months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding: 0; text-indent: 0">Sale of goods</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,450</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding: 0; text-indent: 0">Services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,913</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">126,053</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding: 0; text-indent: 0">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">74,913</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">268,503</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Revenue by geographic location:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Three months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding: 0; text-indent: 0">United States</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">74,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">126,053</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding: 0; text-indent: 0">Non-United States</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">142,450</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding: 0; text-indent: 0">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">74,913</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">268,503</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Property, Plant and Equipment   The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 5 years as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; text-align: justify">Lab equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 47%; text-align: right">5 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture, fixtures and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3 years</td><td style="text-align: left"> </td></tr> </table>    Intangibles Assets   Intangibles assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisition in 2018 has also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.   Goodwill   Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceed their fair value. The Company does not amortize goodwill in accordance with ASC 350.   Long-lived Assets   Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value.   Earnings per Share   Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of July 31, 2019 and 2018, there were 57,500 and 182,500 common stock equivalents outstanding, respectively, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.   Stock-Based Compensation   ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).   For the six months ended July 31, 2018, the Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity - Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. As of February 1, 2019, pursuant to ASU 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.   Leases   In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.   The Company adopted ASU 2016-02 as amended effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, the Company elected to utilize the Comparative Under 840 Option whereby the Company will continue to present prior period financial statements and disclosures under ASC 840. In addition, the Company elected the transition package of three practical expedients permitted under the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.   Adoption of the new standard resulted in the recording of right-to-use assets in the amount of $28,827 and lease liabilities related to operating leases in the amount of $28,827 on the Company’s consolidated balance sheet as of February 1, 2019. See Note 10, Leases, for Topic 842 disclosures in connection with the adoption of ASU 2016-02.   Recent Accounting Standards   The Company has implemented all new pronouncements, including the adoption of ASC 842 and 718, that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements or results of operations.

4. DEBT   On September 12, 2017, the Company borrowed $15,000 on an interest-free basis from a minority stockholder. In April 2018, the Company borrowed an additional $25,000 from the minority stockholder. In July 2019, the Company borrowed an additional $50,000. The loans are interest free and due upon demand. The balance due on such loans was $90,000 on July 31, 2019, and $40,000 on January 31, 2019, which is included in notes payable.

Principles of Consolidation   The consolidated financial statements of the Company include the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018.

Use of Estimates   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities.  On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances.  The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  Actual results could differ from those estimates.

Revenue Recognition   The Company recognized revenue in accordance with Topic 606 “Revenue from Contracts with Customers. Topic 606 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic 606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.   Upon adoption, Topic 606 replaced most existing revenue recognition guidance in U.S. GAAP. The adoption of Topic the new revenue recognition standards did not have any impact on its consolidated financial statements since the Company did not recognize any revenue prior to the third quarter of 2018, and all revenue is recognized pursuant to Topic 606.   Revenue Service Types   The following is a description of the Company’s revenue service types, which include professional services and sale of goods:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Professional services include contract research and development related services with clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Sales revenues are derived from the sale of products. To date, sales related to consumer products sold to the Company’s South Korean distributor. Upon receipt of a purchase order, the Company has the order filled and shipped.</td> </tr></table>    Contracts with Customers   A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) the Company determines that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.   Performance Obligations   A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue types, the performance obligation is satisfied at different times. The Company‘s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When the Company performs professional service work, it recognizes revenue when it has the right to invoice the customer for the work completed, which typically occurs on a monthly basis for the work performed during that month.   All revenue recognized in the statement of operations is revenue from contracts with customers.   Disaggregation of Revenues   The Company disaggregates its revenue from contracts with customers by service type and by geographical location. The following tables set forth revenue by service type and by geographical location.   Revenue by service type:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Three months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding: 0; text-indent: 0">Sale of goods</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,450</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding: 0; text-indent: 0">Services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,913</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">126,053</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding: 0; text-indent: 0">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">74,913</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">268,503</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Revenue by geographic location:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Three months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding: 0; text-indent: 0">United States</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">74,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">126,053</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding: 0; text-indent: 0">Non-United States</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">142,450</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding: 0; text-indent: 0">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">74,913</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">268,503</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

Property, Plant and Equipment   The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 5 years as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; text-align: justify">Lab equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 47%; text-align: right">5 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture, fixtures and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3 years</td><td style="text-align: left"> </td></tr></table>

Intangibles Assets   Intangibles assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisition in 2018 has also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.

Goodwill   Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceed their fair value. The Company does not amortize goodwill in accordance with ASC 350.

Long-lived Assets   Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value.

Earnings per Share   Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of July 31, 2019 and 2018, there were 57,500 and 182,500 common stock equivalents outstanding, respectively, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

Stock-Based Compensation   ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).   For the six months ended July 31, 2018, the Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity - Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. As of February 1, 2019, pursuant to ASU 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.

Leases   In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.   The Company adopted ASU 2016-02 as amended effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, the Company elected to utilize the Comparative Under 840 Option whereby the Company will continue to present prior period financial statements and disclosures under ASC 840. In addition, the Company elected the transition package of three practical expedients permitted under the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.   Adoption of the new standard resulted in the recording of right-to-use assets in the amount of $28,827 and lease liabilities related to operating leases in the amount of $28,827 on the Company’s consolidated balance sheet as of February 1, 2019. See Note 10, Leases, for Topic 842 disclosures in connection with the adoption of ASU 2016-02.

Recent Accounting Standards   The Company has implemented all new pronouncements, including the adoption of ASC 842 and 718, that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements or results of operations.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Three months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding: 0; text-indent: 0">Sale of goods</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,450</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding: 0; text-indent: 0">Services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,913</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">126,053</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding: 0; text-indent: 0">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">74,913</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">268,503</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Three months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended July 31,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding: 0"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding: 0; text-indent: 0">United States</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">74,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">126,053</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding: 0; text-indent: 0">Non-United States</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">142,450</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding: 0; text-indent: 0">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">74,913</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">268,503</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; text-align: justify">Lab equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 47%; text-align: right">5 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture, fixtures and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3 years</td><td style="text-align: left"> </td></tr> </table>

2500000 false

62500

2250000

1850000

400000

0.06

10. LEASES   The Company has operating leases for its facilities used for research and development, sales and administration. These leases have remaining lease terms of less than one year. Certain of these leases contain options to extend the term of the lease and certain of these leases contain options to terminate the lease within a specified period of time. The options to extend or terminate a lease are included in the lease term when it is reasonably likely that the Company will elect that option. The Company is not a party to any material sublease arrangements.   The components of lease expense, which are included in cost of revenues and general and administrative expense, based on the underlying uses of the right of use asset, were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center">Six Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">July 31, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Amortization of right-of-use asset</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,609</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest on lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,145</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Total Lease Cost</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,754</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>    Supplementary cash flow information related to leases are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Six Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">July 31, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-left: 0.125in">Operating cash flows from operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,609</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Operating leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">28,827</td><td style="text-align: left"> </td></tr> </table>   Supplementary balance sheet information related to leases are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>Operating Leases:</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Operating lease right-of -use assets</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">19,218</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,652</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-Average Remaining Lease Term:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-Average Discount Rate:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.24</td><td style="text-align: left">%</td></tr> </table>   Our discount rate is based on our incremental borrowing rate.   Maturities of lease liabilities were as follows as of July 31, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left"></td><td> </td> <td colspan="2" style="text-align: center">Operating</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Year Ending January 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Leases</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2020-remaining</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,320</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2021-remaining</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,320</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total undiscounted cash flows</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,640</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(988</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Present value of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,652</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Life</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">182,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> 0.35 years </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired/Cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(125,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding-period ending July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">57,500</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"> 0.50 years </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,466,250</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable - period ending July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">57,500</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"> 0.50 years </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,466,250</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td></td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Life</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, January 31, 2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Granted</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">25.64</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> 0.05 years </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">232,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired/Cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding-period ending July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable - period ending July 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

57500

182500

14.00

57500 P0Y6M0D 14.00 14.00 232750

1. ORGANIZATION AND DESCRIPTION OF BUSINESS   Organization   Nutriband Inc. (the "Company") is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd., an Irish company which was formed by the Company's chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.   On August 1, 2018, the Company acquired 4P Therapeutics LLC ("4P Therapeutics") for $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and $400,000, and a royalty payable to the former owner of 4P Therapeutics, of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into the agreement to acquire 4P Therapeutics.   4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company's business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the "FDA"). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its consumer products are not being marketed in the United States.   With the acquisition of 4P Therapeutics, 4P Therapeutics' drug development business became the Company's principal business. The Company's approach is to use generic drugs that are off patent and incorporate them into the Company's transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical transdermal products.   Reverse Stock Split and Reduction in Authorized Common Stock   On June 25, 2019, the Company effected one-for-four reverse split, pursuant to which each share of common stock became and was converted into 0.25 share of common stock, and the Company decreased its authorized common stock from 100,000,000 shares to 25,000,000 shares. The reverse split became effective in the marketplace on July 24, 2019. All share and per share information in these financial statements retroactively reflect the reverse split.   Going Concern   The Company's consolidated financial statements for the six months ended July 31, 2019 have been prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities in the normal course of business. The Company did not generate any revenue prior to the quarter ended October 31, 2018. For the six months ended July 31, 2019, the Company generated revenue of $268,503 on which it recorded cost of revenues of $316,753 and a loss from operations of $1,022,773. The Company requires substantial funding to execute its strategic business plan. Successful business operations and its transition to attaining profitability are dependent upon obtaining significant additional financing, generating revenue primarily from its professional services to cover its overhead, developing its products, and obtaining FDA approval to market any product it develops and implementing a marketing program for such products. The Company will not be able to generate any revenue from its proposed transdermal pharmaceutical products without FDA approval. These factors raise substantial doubt about ability of the Company to continue as a going concern.

The Company acquired 4P Therapeutics LLC ("4P Therapeutics") for $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and $400,000, and a royalty payable to the former owner of 4P Therapeutics, of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into the agreement to acquire 4P Therapeutics.

EX-101.SCH 6 ntrb-20190731.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Unaudited Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Unaudited Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Acquisition of Business link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Warrants and Options link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Acquisition of Business (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Warrants and Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Summary of Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Acquisition of Business (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Acquisition of Business (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Acquisition of Business (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Intangible Assets and Goodwill (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Intangible Assets and Goodwill (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Intangible Assets and Goodwill (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Warrants and Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Warrants and Options (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Leases (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Leases (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Leases (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ntrb-20190731_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 ntrb-20190731_def.xml XBRL DEFINITION FILE EX-101.LAB 9 ntrb-20190731_lab.xml XBRL LABEL FILE Equity Components [Axis] Warrants [Member] Common Stock [Member] Property, Plant and Equipment, Type [Axis] Equipment [Member] Range [Axis] Maximun [Member] Minimum [Member] Additional Paid-In Capital Other Comprehensive Income / Loss Retained Earnings / Accumulated Deficit Furniture, fixtures and equipment [Member] Geographical [Axis] Non-US [Member] UNITED STATES [Member] Related Party [Axis] Advanced Health Brands [Member] Asset Class [Axis] Finite-Lived Intangible Assets [Member] Finite-Lived Intangible Assets by Major Class [Axis] Customer-Related Intangible Assets [Member] Intellectual Property [Member] Goodwill [Member] Leases [Member] Trademark and Intellectual Property [Member] Option Indexed to Issuer's Equity, Type [Axis] Employee Stock Option [Member] Title of Individual [Axis] Defendants [Member] Common stock to be issued [Member] 4P Therapeutics LLC [Member] Executives [Member] Ann Sheridan [Member] Minority Stockholder [Member] Health Brans, Inc. [Member] Director [Member] Advisory Board [Member] Non-affiliated [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Exercise Price Range [Axis] Range Of Exercise Prices Three [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Filer Category Entity Current Reporting Status Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Interactive Data Current Entity Incorporation State Country Code Entity File Number Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash and cash equivalents Accounts receivable Prepaid expenses Total Current Assets PROPERTY & EQUIPMENT-net OTHER ASSETS: Goodwill Right of use asset-net Intangible assets-net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable and accrued expenses Customer deposits Operating lease liability Note payable Total Current Liabilities Commitments and Contingencies STOCKHOLDERS' EQUITY: Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding Common stock, $.001 par value, 25,000,000 shares authorized; 5,423,956 shares issued and outstanding at July 31, 2019 and January 31, 2019 Additional paid-in-capital Accumulated other comprehensive loss Accumulated deficit Total Stockholders' Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Costs and expenses: Cost of revenues Selling, general and administrative expenses Total Costs and Expenses Loss from operations Other income (expense) Interest expense Loss from operations before provision for income taxes Provision for income taxes Net loss Net loss per share of common stock-basic and diluted Weighted average shares of common stock outstanding - basic and diluted Other Comprehensive Income (Loss): Net loss Foreign currency translation adjustment Total Comprehensive Income (Loss) Statement [Table] Statement [Line Items] Common Stock Additional Paid In Capital Accumulated Other Comprehensive Income(Loss) Accumulated Deficit Common stock to be issued Balance Balance, shares Issuance of common stock for services Issuance of common stock for services, shares Sale of common stock for cash Sale of common stock for cash, shares Common stock issued upon the exercise of warrants Common stock issued upon the exercise of warrants, shares Common stock issued for acquisition Common stock issued for acquisition, shares Issuance of warrants for services Net loss Foreign currency translation adjustment Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Expenses paid on behalf of the Company by related party Depreciation and amortization Amortization of right of use asset Stock-based compensation Changes in operating assets and liabilities: Inventories Accounts receivable Prepaid expenses Deferred revenue Deposit on sales Operating lease liability Accounts payable and accrued expenses Net Cash Used In Operating Activities Cash flows from investing activities: Purchase of equipment Net Cash Used in Investing Activities Cash flows from financing activities: Payment of bank overdraft Proceeds from sale of common stock Proceeds from exercise of warrants Proceeds from notes payable Payment of notes payable Proceeds from related parties Payment of related party payables Net Cash Provided by Financing Activities Effect of exchange rate on cash Net change in cash Cash and cash equivalents - Beginning of period Cash and cash equivalents - End of period Supplementary information: Cash paid for: Interest Income taxes Supplemental disclosure of non-cash investing and financing activities Common stock to be issued for services Adoption of ASC 842 Operating lease asset and liability Common stock issued for deposit on acquisition Accounting Policies [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS Summary Of Significant Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Debt Disclosure [Abstract] DEBT Business Combinations [Abstract] ACQUISITION OF BUSINESS Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS AND GOODWILL Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Equity [Abstract] COMMON STOCK Warrants and Rights Note Disclosure [Abstract] WARRANTS AND OPTIONS Leases [Abstract] EX-101.PRE 10 ntrb-20190731_pre.xml XBRL PRESENTATION FILE XML 11 R6.htm IDEA: XBRL DOCUMENT

Unaudited Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Cash flows from operating activities:
Net loss	$ (1,023,918)	$ (2,326,870)
Adjustments to reconcile net loss to net cash used in operating activities:
Expenses paid on behalf of the Company by related party		24,300
Depreciation and amortization	36,094	347
Amortization of right of use asset	9,609
Stock-based compensation	252,700	1,763,950
Changes in operating assets and liabilities:
Inventories		(50,473)
Accounts receivable	(57,454)	263
Prepaid expenses	34,225	95,000
Deferred revenue		49,000
Deposit on sales	(71,225)
Operating lease liability	(9,175)
Accounts payable and accrued expenses	318,576	61,541
Net Cash Used In Operating Activities	(510,568)	(382,942)
Cash flows from investing activities:
Purchase of equipment		(4,163)
Net Cash Used in Investing Activities		(4,163)
Cash flows from financing activities:
Payment of bank overdraft		(762)
Proceeds from sale of common stock		1,000,000
Proceeds from exercise of warrants		500,000
Proceeds from notes payable	50,000	25,000
Payment of notes payable		(1,820)
Proceeds from related parties		2,500
Payment of related party payables		(41,038)
Net Cash Provided by Financing Activities	50,000	1,483,880
Effect of exchange rate on cash	(252)	406
Net change in cash	(460,820)	1,097,181
Cash and cash equivalents - Beginning of period	474,653
Cash and cash equivalents - End of period	13,833	1,097,181
Cash paid for:
Interest
Income taxes
Supplemental disclosure of non-cash investing and financing activities
Common stock to be issued for services		1,763,950
Adoption of ASC 842 Operating lease asset and liability	28,827
Common stock issued for deposit on acquisition		$ 1,850,000

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Jul. 31, 2019	Jan. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 13,833	$ 474,653
Accounts receivable	70,542	13,088
Prepaid expenses	68,500	102,725
Total Current Assets	152,875	590,466
PROPERTY & EQUIPMENT-net	128,588	146,147
OTHER ASSETS:
Goodwill	1,719,235	1,719,235
Right of use asset-net	19,218
Intangible assets-net	333,235	351,770
TOTAL ASSETS	2,353,151	2,807,618
CURRENT LIABILITIES:
Accounts payable and accrued expenses	610,357	291,781
Customer deposits		71,225
Operating lease liability	19,652
Note payable	90,000	40,000
Total Current Liabilities	720,009	403,006
Commitments and Contingencies
STOCKHOLDERS' EQUITY:
Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding
Common stock, $.001 par value, 25,000,000 shares authorized; 5,423,956 shares issued and outstanding at July 31, 2019 and January 31, 2019	5,424	5,424
Additional paid-in-capital	8,832,590	8,579,890
Accumulated other comprehensive loss	(304)	(52)
Accumulated deficit	(7,204,568)	(6,180,650)
Total Stockholders' Equity	1,633,142	2,404,612
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,353,151	$ 2,807,618

XML 13 R37.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill (Details) - Intangible Assets [Member] - USD ($)	Jul. 31, 2019	Jan. 31, 2019
Total	$ 2,089,935	$ 2,089,935
Less: Accumulated amortization	(37,465)	(18,930)
Net Intangible Assets	2,052,470	2,071,005
Customer base [Member]
Total	136,500	136,500
Intellectual property [Member]
Total	234,200	234,200
Goodwill [Member]
Total	$ 1,719,235	$ 1,719,235

XML 14 R33.htm IDEA: XBRL DOCUMENT

Debt (Details) - USD ($)	Jul. 31, 2019	Jan. 31, 2019	Apr. 30, 2018	Sep. 12, 2017
Debt (Textual)
Balance due	$ 90,000	$ 40,000
Minority Stockholder [Member]
Debt (Textual)
Borrowed amount	$ 50,000		$ 25,000	$ 15,000

XML 15 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jul. 31, 2019

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

12. SUBSEQUENT EVENTS

On August 14, 2019, the Company borrowed an additional $50,000 from a minority stockholder, bringing the total loans from the minority stockholder to $140,000. See Note 4.

XML 16 R10.htm IDEA: XBRL DOCUMENT

Debt

6 Months Ended

Jul. 31, 2019

Debt Disclosure [Abstract]

DEBT

4. DEBT

XML 17 R14.htm IDEA: XBRL DOCUMENT

Common Stock

6 Months Ended

Jul. 31, 2019

Equity [Abstract]

COMMON STOCK

8. COMMON STOCK

During the six months ended July 31, 2018, the Company issued:

(i)

68,000 shares of common stock, valued at $1,419,300, issued to executive officers and their affiliates;

(ii)

7,500 shares of common stock, valued at $222,000, issued to the Company's independent directors;

(iii)

2,500 shares of common stock, valued at $74,000, issued to the Company's advisory board member; and

(iv)

2,500 shares of common stock, valued at $48,600, issued to a non-affiliated party for services.

On July 31, 2018, the Company issued 62,500 shares of common stock valued at $1,850,000 representing a portion of the purchase price for the equity of 4P Therapeutics. See Notes 4 and 6.

On May 24, 2019, the Board of Directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock ("Series A Preferred Stock"). On June 20, 2019, the Series A preferred Stock was terminated and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the Board of Directors.

XML 18 R22.htm IDEA: XBRL DOCUMENT

Acquisition of Business (Tables)

6 Months Ended

Jul. 31, 2019

Business Combinations [Abstract]

Schedule of net assets acquired

	Fair Value Recognized
	On Acquisition
Equipment	$	160,065
Customer base		136,500
Intellectual property		191,900
Trademark		42,300
Goodwill		1,719,235
Net assets acquired	$	2,250,000
Satisfied by:
Common stock issued	$	(1,850,000	)
Cash outflows on acquisition		(400,000	)

Schedule of unaudited pro forma condensed financial information

	Six months ended July 31, 2018
	As Reported			Pro Forma
Revenue	$	-		$	331,864
Net loss	$	(2,326,870	)	$	(2,421,391	)
Loss per share of common stock (basic and diluted)	$	(0.44	)	$	(0.46	)

XML 19 R26.htm IDEA: XBRL DOCUMENT

Organization and Description of Business (Details) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	Aug. 01, 2018	Jun. 25, 2019	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Organization and Description of Business (Textual)
Description of acquired	The Company acquired 4P Therapeutics LLC ("4P Therapeutics") for $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and $400,000, and a royalty payable to the former owner of 4P Therapeutics, of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into the agreement to acquire 4P Therapeutics.
Revenue			$ 74,913		$ 268,503
Cost of revenues					316,753
Loss from operations			$ (450,565)	$ (1,878,772)	$ (1,023,918)	$ (2,326,870)
Reverse stock split and reduction, description		The Company effected one-for-four reverse split, pursuant to which each share of common stock became and was converted into 0.25 share of common stock, and the Company decreased its authorized common stock from 100,000,000 shares to 25,000,000 shares. The reverse split became effective in the marketplace on July 24, 2019. All share and per share information in these financial statements retroactively reflect the reverse split.

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 20 R47.htm IDEA: XBRL DOCUMENT

Leases (Details 2) - USD ($)	Jul. 31, 2019	Jan. 31, 2019
Operating Leases:
Operating lease right-of -use assets	$ 19,218
Operating lease liabilities	$ 19,652
Weighted-Average Remaining Lease Term:
Operating leases	1 year
Weighted-Average Discount Rate:
Operating leases	9.24%

XML 21 R43.htm IDEA: XBRL DOCUMENT

Warrants and Options (Details)	6 Months Ended
Warrants and Options (Details)	Jul. 31, 2019 USD ($) $ / shares shares
Options [Member]
Shares
Outstanding, Beginning Balance \| shares
Granted \| shares	25,000
Outstanding, Ending Balance \| shares
Exercisable \| shares
Exercise Price
Outstanding, Beginning Balance
Granted	25.64
Expired/Cancelled	25.64
Exercised
Outstanding, Ending Balance
Exercisable
Remaining Life
Granted	18 days
Intrinsic Value
Outstanding, Beginning Balance \| $
Granted \| $	232,750
Outstanding, Ending Balance \| $
Exercisable, Ending Balance \| $
Warrant [Member]
Shares
Outstanding, Beginning Balance \| shares	182,500
Granted \| shares
Outstanding, Ending Balance \| shares	57,500
Exercisable \| shares	57,500
Exercise Price
Outstanding, Beginning Balance	$ 6.32
Granted
Expired/Cancelled	2.80
Exercised
Outstanding, Ending Balance	14.00
Exercisable	$ 14.00
Remaining Life
Outstanding, Beginning period	4 months 6 days
Outstanding, Ending period	6 months
Exercisable	6 months
Intrinsic Value
Outstanding, Beginning Balance \| $	$ 4,101,000
Granted \| $
Outstanding, Ending Balance \| $	1,466,250
Exercisable, Ending Balance \| $	$ 1,466,250

XML 22 R23.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill (Tables)

6 Months Ended

Jul. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization

	July 31,			January 31,
	2019			2019
Customer base	$	136,500		$	136,500
Intellectual property		234,200			234,200
Goodwill		1,719,235			1,719,235

Total		2,089,935			2,089,935

Less: Accumulated amortization		(37,465	)		(18,930	)

Net Intangible Assets	$	2,052,470		$	2,071,005

Schedule of changes in intangible assets

Intangible assets consist of:

Intellectual property	$	234,200
Accumulated amortization		(23,815	)
Book value at July 31, 2019	$	210,385

Customer base	$	136,500
Accumulated amortization		(13,650	)
Book value at July 31, 2019	$	122,850
Total Intangible Assets, Net	$	333,235

Schedule of estimated amortization

	Trademarks and Intellectual		Customer
Estimated Amortization:	Property		Base		Total
Year Ended January 31,
2020	$	11,710	$	6,825	$	18,535
2021		23,420		13,650		37,070
2022		23,420		13,650		37,070
2023		23,420		13,650		37,070
2024 and thereafter		128,415		75,075		203,490
	$	210,385	$	122,850	$	333,235

XML 23 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Revenue by service type
Sale of goods			$ 142,450
Services	74,913		126,053
Total	$ 74,913		$ 268,503

XML 24 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 25 R46.htm IDEA: XBRL DOCUMENT

Leases (Details 1)	6 Months Ended
Leases (Details 1)	Jul. 31, 2019 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 9,609
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 28,827

XML 26 R42.htm IDEA: XBRL DOCUMENT

Common Stock (Details) - USD ($)			1 Months Ended				3 Months Ended	6 Months Ended
Common Stock (Details) - USD ($)	May 27, 2018	May 02, 2018	Jun. 20, 2019	May 24, 2019	Nov. 30, 2018	Jun. 02, 2018	Jul. 31, 2018	Jul. 31, 2018	Jul. 31, 2019	Jan. 31, 2019
Common Stock (Textual)
Shares issued for services, value							$ 1,486,450	$ 1,763,950
Common stock, value							$ 1,000,000	$ 1,000,000
Common stock issued									5,423,956	5,423,956
Series A Preferred Stock [Member]
Common Stock (Textual)
Preferred stock shares designated				2,500,000
Unissued preferred stock shares			2,500,000
Executives [Member]
Common Stock (Textual)
Issuance shares of common stock, shares								68,000
Common stock, value								$ 1,419,300
Director [Member]
Common Stock (Textual)
Issuance shares of common stock, shares								7,500
Common stock, value								$ 222,000
Non-affiliated [Member]
Common Stock (Textual)
Issuance shares of common stock, shares								2,500
Common stock, value								$ 48,600
Advisory Board [Member]
Common Stock (Textual)
Issuance shares of common stock, shares								2,500
Common stock, value								$ 74,000
Common stock [Member]
Common Stock (Textual)
Shares issued for services							80,500	62,500
Shares issued for services, value							$ 80	$ 1,850,000
Issuance shares of common stock, shares		62,500					62,500	62,500
Common stock, value							$ 63	$ 63
Proceeds from common stock received		$ 1,000,000
Warrant to purchase of common stock		62,500
Warrant maturity date		30 days
Exercise price of warrants		$ 16.00
Common stock warrants exercised	$ 500,000
Common stock warrants exercised, shares	31,250					31,250
Common stock [Member] \| Advanced Health Brands [Member]
Common Stock (Textual)
Common stock issued					50,000
Shares cancelled date					Jan. 31, 2019

XML 27 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 28 R7.htm IDEA: XBRL DOCUMENT

Organization and Description of Business

6 Months Ended

Jul. 31, 2019

Accounting Policies [Abstract]

ORGANIZATION AND DESCRIPTION OF BUSINESS

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Organization

Nutriband Inc. (the "Company") is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd., an Irish company which was formed by the Company's chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.

On August 1, 2018, the Company acquired 4P Therapeutics LLC ("4P Therapeutics") for $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and $400,000, and a royalty payable to the former owner of 4P Therapeutics, of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into the agreement to acquire 4P Therapeutics.

4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company's business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the "FDA"). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its consumer products are not being marketed in the United States.

With the acquisition of 4P Therapeutics, 4P Therapeutics' drug development business became the Company's principal business. The Company's approach is to use generic drugs that are off patent and incorporate them into the Company's transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical transdermal products.

Reverse Stock Split and Reduction in Authorized Common Stock

Going Concern

The Company's consolidated financial statements for the six months ended July 31, 2019 have been prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities in the normal course of business. The Company did not generate any revenue prior to the quarter ended October 31, 2018. For the six months ended July 31, 2019, the Company generated revenue of $268,503 on which it recorded cost of revenues of $316,753 and a loss from operations of $1,022,773. The Company requires substantial funding to execute its strategic business plan. Successful business operations and its transition to attaining profitability are dependent upon obtaining significant additional financing, generating revenue primarily from its professional services to cover its overhead, developing its products, and obtaining FDA approval to market any product it develops and implementing a marketing program for such products. The Company will not be able to generate any revenue from its proposed transdermal pharmaceutical products without FDA approval. These factors raise substantial doubt about ability of the Company to continue as a going concern.

XML 29 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2019	Jan. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	5,423,956	5,423,956
Common stock, shares outstanding	5,423,956	5,423,956

XML 30 R36.htm IDEA: XBRL DOCUMENT

Acquisition of Business (Details Textual) - 4P Therapeutics LLC [Member] - USD ($)	Apr. 05, 2018	Aug. 01, 2018
Acquisition of Business (Textual)
Acquired common stock, shares	62,500
Acquired common stock value	$ 1,850,000
Acquired consisting	2,250,000
Acquired consisting gross	$ 400,000
Payment of royalty percentage	6.00%
Acquired of membership interests		100.00%

XML 31 R32.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Textual) - USD ($)	6 Months Ended
Property and Equipment (Details Textual) - USD ($)	Jul. 31, 2019	Jul. 31, 2018
Property and Equipment (Textual)
Depreciation expense	$ 17,559	$ 347

XML 32 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 116 310 1 false 31 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://nutriband.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://nutriband.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://nutriband.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss) Sheet http://nutriband.com/role/UnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss) Statements 4 false false R5.htm 00000005 - Statement - Unaudited Consolidated Statements of Stockholders' Equity Sheet http://nutriband.com/role/UnauditedConsolidatedStatementsOfStockholdersEquity Unaudited Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Unaudited Consolidated Statements of Cash Flows Sheet http://nutriband.com/role/UnauditedConsolidatedStatementsOfCashFlows Unaudited Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Description of Business Sheet http://nutriband.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://nutriband.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Property and Equipment Sheet http://nutriband.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 00000010 - Disclosure - Debt Sheet http://nutriband.com/role/Debt Debt Notes 10 false false R11.htm 00000011 - Disclosure - Acquisition of Business Sheet http://nutriband.com/role/AcquisitionOfBusiness Acquisition of Business Notes 11 false false R12.htm 00000012 - Disclosure - Intangible Assets and Goodwill Sheet http://nutriband.com/role/IntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 12 false false R13.htm 00000013 - Disclosure - Related Party Transactions Sheet http://nutriband.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Common Stock Sheet http://nutriband.com/role/CommonStock Common Stock Notes 14 false false R15.htm 00000015 - Disclosure - Warrants and Options Sheet http://nutriband.com/role/WarrantsAndOptions Warrants and Options Notes 15 false false R16.htm 00000016 - Disclosure - Leases Sheet http://nutriband.com/role/Leases Leases Notes 16 false false R17.htm 00000017 - Disclosure - Contingencies Sheet http://nutriband.com/role/Contingencies Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://nutriband.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://nutriband.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://nutriband.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://nutriband.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://nutriband.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Property and Equipment (Tables) Sheet http://nutriband.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://nutriband.com/role/PropertyAndEquipment 21 false false R22.htm 00000022 - Disclosure - Acquisition of Business (Tables) Sheet http://nutriband.com/role/AcquisitionOfBusinessTables Acquisition of Business (Tables) Tables http://nutriband.com/role/AcquisitionOfBusiness 22 false false R23.htm 00000023 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://nutriband.com/role/IntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://nutriband.com/role/IntangibleAssetsAndGoodwill 23 false false R24.htm 00000024 - Disclosure - Warrants and Options (Tables) Sheet http://nutriband.com/role/WarrantsTables Warrants and Options (Tables) Tables http://nutriband.com/role/WarrantsAndOptions 24 false false R25.htm 00000025 - Disclosure - Leases (Tables) Sheet http://nutriband.com/role/LeasesTables Leases (Tables) Tables http://nutriband.com/role/Leases 25 false false R26.htm 00000026 - Disclosure - Organization and Description of Business (Details) Sheet http://nutriband.com/role/OrganizationAndDescriptionOfBusinessDetails Organization and Description of Business (Details) Details http://nutriband.com/role/OrganizationAndDescriptionOfBusiness 26 false false R27.htm 00000027 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://nutriband.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://nutriband.com/role/SummaryOfSignificantAccountingPoliciesTables 27 false false R28.htm 00000028 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://nutriband.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://nutriband.com/role/SummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - Summary of Significant Accounting Policies (Details 2) Sheet http://nutriband.com/role/SummaryOfSignificantAccountingPoliciesDetails2 Summary of Significant Accounting Policies (Details 2) Details http://nutriband.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 00000030 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://nutriband.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://nutriband.com/role/SummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 00000031 - Disclosure - Property and Equipment (Details) Sheet http://nutriband.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://nutriband.com/role/PropertyAndEquipmentTables 31 false false R32.htm 00000032 - Disclosure - Property and Equipment (Details Textual) Sheet http://nutriband.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) Details http://nutriband.com/role/PropertyAndEquipmentTables 32 false false R33.htm 00000033 - Disclosure - Debt (Details) Sheet http://nutriband.com/role/DebtDetails Debt (Details) Details http://nutriband.com/role/Debt 33 false false R34.htm 00000034 - Disclosure - Acquisition of Business (Details) Sheet http://nutriband.com/role/AcquisitionOfBusinessDetailss Acquisition of Business (Details) Details http://nutriband.com/role/AcquisitionOfBusinessTables 34 false false R35.htm 00000035 - Disclosure - Acquisition of Business (Details 1) Sheet http://nutriband.com/role/AcquisitionOfBusinessDetails1 Acquisition of Business (Details 1) Details http://nutriband.com/role/AcquisitionOfBusinessTables 35 false false R36.htm 00000036 - Disclosure - Acquisition of Business (Details Textual) Sheet http://nutriband.com/role/AcquisitionOfBusinessDetailssTextual Acquisition of Business (Details Textual) Details http://nutriband.com/role/AcquisitionOfBusinessTables 36 false false R37.htm 00000037 - Disclosure - Intangible Assets and Goodwill (Details) Sheet http://nutriband.com/role/IntangibleAssetsAndGoodwillDetails Intangible Assets and Goodwill (Details) Details http://nutriband.com/role/IntangibleAssetsAndGoodwillTables 37 false false R38.htm 00000038 - Disclosure - Intangible Assets and Goodwill (Details 1) Sheet http://nutriband.com/role/IntangibleAssetsAndGoodwillDetails1 Intangible Assets and Goodwill (Details 1) Details http://nutriband.com/role/IntangibleAssetsAndGoodwillTables 38 false false R39.htm 00000039 - Disclosure - Intangible Assets and Goodwill (Details 2) Sheet http://nutriband.com/role/IntangibleAssetsAndGoodwillDetails2 Intangible Assets and Goodwill (Details 2) Details http://nutriband.com/role/IntangibleAssetsAndGoodwillTables 39 false false R40.htm 00000040 - Disclosure - Intangible Assets and Goodwill (Details Textual) Sheet http://nutriband.com/role/IntangibleAssetsAndGoodwillDetailsTextual Intangible Assets and Goodwill (Details Textual) Details http://nutriband.com/role/IntangibleAssetsAndGoodwillTables 40 false false R41.htm 00000041 - Disclosure - Related Party Transactions (Details) Sheet http://nutriband.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://nutriband.com/role/RelatedPartyTransactions 41 false false R42.htm 00000042 - Disclosure - Common Stock (Details) Sheet http://nutriband.com/role/CommonStockDetails Common Stock (Details) Details http://nutriband.com/role/CommonStock 42 false false R43.htm 00000043 - Disclosure - Warrants and Options (Details) Sheet http://nutriband.com/role/WarrantsAndOptionsDetails Warrants and Options (Details) Details http://nutriband.com/role/WarrantsTables 43 false false R44.htm 00000044 - Disclosure - Warrants and Options (Details 1) Sheet http://nutriband.com/role/WarrantsAndOptionsDetails1 Warrants and Options (Details 1) Details http://nutriband.com/role/WarrantsTables 44 false false R45.htm 00000045 - Disclosure - Leases (Details) Sheet http://nutriband.com/role/LeasesDetails Leases (Details) Details http://nutriband.com/role/LeasesTables 45 false false R46.htm 00000046 - Disclosure - Leases (Details 1) Sheet http://nutriband.com/role/LeasesDetails1 Leases (Details 1) Details http://nutriband.com/role/LeasesTables 46 false false R47.htm 00000047 - Disclosure - Leases (Details 2) Sheet http://nutriband.com/role/LeasesDetails2 Leases (Details 2) Details http://nutriband.com/role/LeasesTables 47 false false R48.htm 00000048 - Disclosure - Leases (Details 3) Sheet http://nutriband.com/role/LeasesDetails3 Leases (Details 3) Details http://nutriband.com/role/LeasesTables 48 false false R49.htm 00000049 - Disclosure - Contingencies (Details) Sheet http://nutriband.com/role/ContingenciesDetails Contingencies (Details) Details http://nutriband.com/role/Contingencies 49 false false R50.htm 00000050 - Disclosure - Subsequent Events (Details) Sheet http://nutriband.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://nutriband.com/role/SubsequentEvents 50 false false All Reports Book All Reports ntrb-20190731.xml ntrb-20190731.xsd ntrb-20190731_cal.xml ntrb-20190731_def.xml ntrb-20190731_lab.xml ntrb-20190731_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true EXCEL 33 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.19.2

Acquisition of Business
6 Months Ended

Jul. 31, 2019

Business Combinations [Abstract]

ACQUISITION OF BUSINESS

5. ACQUISITION OF BUSINESS

On August 1, 2018, the Company acquired 100% of the membership interests of 4P Therapeutics, pursuant to an agreement dated April 5, 2018, for $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and $400,000, and a royalty payable to the former owner of 4P Therapeutics, of 6% on all revenue generated by us from the abuse deterrent intellectual property that had been developed by 4P Therapeutics. The primary purpose of the acquisition is to acquire the intellectual property of 4P Therapeutics and complete the development and seek FDA approval on a number of transdermal pharmaceutical products under development by 4P Therapeutics which are in the preclinical stage. As a result of the acquisition of 4P Therapeutics, the Company has a pipeline of potential products. Acquisition costs, which were minimal, have been expensed as incurred in accordance with ASC 350.

Details of the net assets acquired are as follows:

Fair Value Recognized

On Acquisition

Equipment $ 160,065

Customer base 136,500

Intellectual property 191,900

Trademark 42,300

Goodwill 1,719,235

Net assets acquired $ 2,250,000

Satisfied by:

Common stock issued $ (1,850,000 )

Cash outflows on acquisition (400,000 )

The following unaudited pro forma condensed financial information presents the combined results of operations of the Company and 4P Therapeutics as if the acquisition occurred as of the beginning of six-month period ended July 31, 2018. The unaudited pro forma condensed financial information is not intended to represent or be indicative of the consolidated results of operations of the Company that would have been reported had the acquisition occurred at the beginning of the period presented and should not be taken as being representation of the future consolidated results of operations of the Company.

Six months ended
July 31, 2018

As Reported Pro Forma

Revenue $ - $ 331,864

Net loss $ (2,326,870 ) $ (2,421,391 )

Loss per share of common stock (basic and diluted) $ (0.44 ) $ (0.46 )

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-URI http://asc.fasb.org/topic&trid=2303972
+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R15.htm IDEA: XBRL DOCUMENT v3.19.2

Warrants and Options
6 Months Ended

Jul. 31, 2019

Warrants and Rights Note Disclosure [Abstract]

WARRANTS AND OPTIONS

9. WARRANTS AND OPTIONS

The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company's common stock issued to non-employees of the Company.

Exercise Remaining Intrinsic

Shares Price Life Value

Outstanding, January 31, 2019 182,500 $ 6.32 0.35 years $ 4,101,000

Granted - - - -

Expired/Cancelled (125,000 ) 2.80 - -

Exercised - - - -

Outstanding-period ending July 31, 2019 57,500 $ 14.00 0.50 years $ 1,466,250

Exercisable - period ending July 31, 2019 57,500 $ 14.00 0.50 years $ 1,466,250

The following table summarizes additional information relating to the warrants outstanding at July 31, 2019:

Range of Number Remaining Contractual Exercise Price for
Shares Number Exercise Price for
Shares

Exercise Prices Outstanding Life(Years) Outstanding Exercisable Exercisable

$ 14.00 57,500 0.50 $ 14.00 57,500 $ 14.00

The following table summarizes the changes in options outstanding and the related price of the shares of the Company's common stock issued to non-employees of the Company.

Exercise Remaining Intrinsic

Shares Price Life Value

Outstanding, January 31, 2019 - $ - - $ -

Granted 25,000 25.64 0.05 years 232,750

Expired/Cancelled (25,000 ) 25.64 - -

Exercised - - - -

Outstanding-period ending July 31, 2019 - $ - - $ -

Exercisable - period ending July 31, 2019 - $ - - $ -

X

- Definition
The entire disclosure of warrants.
+ References
No definition available.
+ Details

Name: ntrb_WarrantsTextBlock

Namespace Prefix: ntrb_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R19.htm IDEA: XBRL DOCUMENT v3.19.2

Summary of Significant Accounting Policies (Policies)
6 Months Ended

Jul. 31, 2019

Summary Of Significant Accounting Policies [Abstract]

Principles of Consolidation
Principles of Consolidation

The consolidated financial statements of the Company include the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018.

Use of Estimates
Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Revenue Recognition
Revenue Recognition

The Company recognized revenue in accordance with Topic 606 “Revenue from Contracts with Customers. Topic 606 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic 606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

Upon adoption, Topic 606 replaced most existing revenue recognition guidance in U.S. GAAP. The adoption of Topic the new revenue recognition standards did not have any impact on its consolidated financial statements since the Company did not recognize any revenue prior to the third quarter of 2018, and all revenue is recognized pursuant to Topic 606.

Revenue Service Types

The following is a description of the Company’s revenue service types, which include professional services and sale of goods:

● Professional services include contract research and development related services with clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.

● Sales revenues are derived from the sale of products. To date, sales related to consumer products sold to the Company’s South Korean distributor. Upon receipt of a purchase order, the Company has the order filled and shipped.



Contracts with Customers

A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) the Company determines that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue types, the performance obligation is satisfied at different times. The Company‘s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When the Company performs professional service work, it recognizes revenue when it has the right to invoice the customer for the work completed, which typically occurs on a monthly basis for the work performed during that month.

All revenue recognized in the statement of operations is revenue from contracts with customers.

Disaggregation of Revenues

The Company disaggregates its revenue from contracts with customers by service type and by geographical location. The following tables set forth revenue by service type and by geographical location.

Revenue by service type:

Three months ended
July 31, Six months ended
July 31,

2019 2018 2019 2018

Sale of goods $ - $ - $ 142,450 $ -

Services 74,913 - 126,053 -

Total $ 74,913 $ - $ 268,503 $ -

Revenue by geographic location:

Three months ended
July 31, Six months ended
July 31,

2019 2018 2019 2018

United States $ 74,913 $ - $ 126,053 $ -

Non-United States - - 142,450 -

Total $ 74,913 $ - $ 268,503 $ -

Property, Plant and Equipment
Property, Plant and Equipment

The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 5 years as follows:

Lab equipment 5 years

Furniture, fixtures and equipment 3 years

Intangibles Assets
Intangibles Assets

Intangibles assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisition in 2018 has also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.

Goodwill
Goodwill

Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceed their fair value. The Company does not amortize goodwill in accordance with ASC 350.

Long-lived Assets
Long-lived Assets

Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value.

Earnings per Share
Earnings per Share

Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of July 31, 2019 and 2018, there were 57,500 and 182,500 common stock equivalents outstanding, respectively, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

Stock-Based Compensation
Stock-Based Compensation

ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

For the six months ended July 31, 2018, the Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity - Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. As of February 1, 2019, pursuant to ASU 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.

Leases
Leases

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.

The Company adopted ASU 2016-02 as amended effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, the Company elected to utilize the Comparative Under 840 Option whereby the Company will continue to present prior period financial statements and disclosures under ASC 840. In addition, the Company elected the transition package of three practical expedients permitted under the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.

Adoption of the new standard resulted in the recording of right-to-use assets in the amount of $28,827 and lease liabilities related to operating leases in the amount of $28,827 on the Company’s consolidated balance sheet as of February 1, 2019. See Note 10, Leases, for Topic 842 disclosures in connection with the adoption of ASU 2016-02.

Recent Accounting Standards
Recent Accounting Standards

The Company has implemented all new pronouncements, including the adoption of ASC 842 and 718, that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements or results of operations.

X

- References
No definition available.
+ Details

Name: ntrb_LeasesPolicyTextBlock

Namespace Prefix: ntrb_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ntrb_SummaryOfSignificantAccountingPoliciesAbstract

Namespace Prefix: ntrb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 1D
-URI http://asc.fasb.org/extlink&oid=116855982&loc=SL116886442-113899

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=116855982&loc=d3e4549-113899

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (m)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R29.htm IDEA: XBRL DOCUMENT v3.19.2

Summary of Significant Accounting Policies (Details 2)
6 Months Ended

Jul. 31, 2019

Lab equipment [Member]

Property, Plant and Equipment 5 years

Furniture, fixtures and equipment [Member]

Property, Plant and Equipment 3 years

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R21.htm IDEA: XBRL DOCUMENT v3.19.2

Property and Equipment (Tables)
6 Months Ended

Jul. 31, 2019

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

July 31, January 31,

2019 2018

Lab equipment $ 144,585 $ 144,585

Furniture, fixtures and equipment 19,643 19,643

164,228 164,228

Less: Accumulated depreciation (35,640 ) (18,081 )

Net Property and Equipment $ 128,588 $ 146,147

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R25.htm IDEA: XBRL DOCUMENT v3.19.2

Leases (Tables)
6 Months Ended

Jul. 31, 2019

Leases [Abstract]

Schedule of components of lease expense

Six Months Ended

July 31, 2019

Amortization of right-of-use asset $ 9,609

Interest on lease liability 1,145

Operating lease costs -

Total Lease Cost $ 10,754

Schedule of cash flow information related to leases

Six Months Ended

July 31, 2019

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases $ 9,609

Right-of-use assets obtained in exchange for lease obligations:

Operating leases $ 28,827

Schedule of balance sheet information

Operating Leases:

Operating lease right-of -use assets $ 19,218

Operating lease liabilities 19,652

Weighted-Average Remaining Lease Term:

Operating leases 1.00

Weighted-Average Discount Rate:

Operating leases 9.24 %

Schedule of maturities of lease liabilities

Operating

Year Ending January 31, Leases

2020-remaining $ 10,320

2021-remaining 10,320

Total undiscounted cash flows 20,640

Less: imputed interest (988 )

Present value of lease liabilities $ 19,652

X

- Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_LeaseCostTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of supplemental cash flow information for the periods presented.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R44.htm IDEA: XBRL DOCUMENT v3.19.2

Warrants and Options (Details 1) - 14.00 [Member]
6 Months Ended

Jul. 31, 2019

$ / shares

shares

Range of Exercise Prices 14.00

Number Outstanding 57,500

Remaining Contractual Life (Years) 6 months

Exercise Price for Shares Outstanding | $ / shares $ 14.00

Number Exercisable 57,500

Exercise Price for Shares Exercisable | $ / shares $ 14.00

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock warrants plan.
+ References
No definition available.
+ Details

Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice

Namespace Prefix: ntrb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants outstanding, including both vested and non-vested warrants.
+ References
No definition available.
+ Details

Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber

Namespace Prefix: ntrb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Change in the weighted average exercise price of warrants outstanding.
+ References
No definition available.
+ Details

Name: ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice

Namespace Prefix: ntrb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for warrants awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: ntrb_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ntrb_RangeOfExercisePricesThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R40.htm IDEA: XBRL DOCUMENT v3.19.2

Intangible Assets and Goodwill (Details Textual) - USD ($)
6 Months Ended

Jul. 31, 2019

Jul. 31, 2018

Intangible Assets and Goodwill (Textual)

Amortization expense of intangible assets $ 18,535 $ 0

X

- Definition
Amortization expense of intangible assets.
+ References
No definition available.
+ Details

Name: ntrb_AmortizationExpenseOfIntangibleAssets

Namespace Prefix: ntrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: ntrb_IntangibleAssetsTextualAbstract

Namespace Prefix: ntrb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R48.htm IDEA: XBRL DOCUMENT v3.19.2

Leases (Details 3)

Jul. 31, 2019

USD ($)

Leases [Abstract]

2020-remaining $ 10,320

2021-remaining 10,320

Total undiscounted cash flows 20,640

Less: imputed interest (988)

Present value of lease liabilities $ 19,652

X

- Definition
Present value of lease liabilities.
+ References
No definition available.
+ Details

Name: ntrb_PresentValueOfLeaseLiabilities

Namespace Prefix: ntrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Future minimum rental payments in aggregate as of the balance sheet date under operating leases.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Future rental payments receivable within one year of the balance sheet date under an operating lease.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Future rental payments receivable within the second year from the balance sheet date under an operating lease.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Disclosure of the unamortized amount of the premium on the note or receivable which is added to the face amount of the receivable or loan. The discount or premium is defined as the difference between the present value and the face amount.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399
+ Details

Name: us-gaap_ReceivableWithImputedInterestPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 43 R5.htm IDEA: XBRL DOCUMENT v3.19.2

Unaudited Consolidated Statements of Stockholders' Equity - USD ($)

Common Stock

Additional Paid In Capital

Accumulated Other Comprehensive Income(Loss)

Accumulated Deficit

Common stock to be issued

Total

Balance at Jan. 31, 2018 $ 5,219 $ 2,966,145 $ (446) $ (2,849,410) $ 121,508

Balance, shares at Jan. 31, 2018 5,219,275

Issuance of common stock for services $ 1,850,000 1,763,870 1,763,950

Issuance of common stock for services, shares 62,500

Sale of common stock for cash $ 63 999,937 1,000,000

Sale of common stock for cash, shares 62,500

Common stock issued upon the exercise of warrants $ 31 499,969 500,000

Common stock issued upon the exercise of warrants, shares 31,250

Common stock issued for acquisition $ 63 1,849,937 1,850,000

Common stock issued for acquisition, shares 62,500

Net loss (2,326,870) (2,326,870)

Foreign currency translation adjustment 398 398

Balance at Jul. 31, 2018 $ 5,456 8,079,858 (48) (5,176,280) 2,908,986

Balance, shares at Jul. 31, 2018 5,456,025

Balance at Apr. 30, 2018 $ 5,219 2,966,145 (300) (3,297,508) 277,500 (48,944)

Balance, shares at Apr. 30, 2018 5,219,275

Issuance of common stock for services $ 80 1,763,870 (277,500) 1,486,450

Issuance of common stock for services, shares 80,500

Sale of common stock for cash $ 63 999,937 1,000,000

Sale of common stock for cash, shares 62,500

Common stock issued upon the exercise of warrants $ 31 499,969 500,000

Common stock issued upon the exercise of warrants, shares 31,250

Common stock issued for acquisition $ 63 1,849,937 1,850,000

Common stock issued for acquisition, shares 62,500

Net loss (1,878,772) (1,878,772)

Foreign currency translation adjustment 252 252

Balance at Jul. 31, 2018 $ 5,456 8,079,858 (48) (5,176,280) 2,908,986

Balance, shares at Jul. 31, 2018 5,456,025

Balance at Jan. 31, 2019 $ 5,424 8,579,890 (52) (6,180,650) 2,404,612

Balance, shares at Jan. 31, 2019 5,423,956

Issuance of warrants for services 252,700 252,700

Net loss (1,023,918) (1,023,918)

Foreign currency translation adjustment (252) (252)

Balance at Jul. 31, 2019 $ 5,424 8,832,590 (304) (7,204,568) 1,633,142

Balance, shares at Jul. 31, 2019 5,423,956

Balance at Apr. 30, 2019 $ 5,424 8,832,590 (304) (6,754,003) 2,083,707

Balance, shares at Apr. 30, 2019 5,423,956

Net loss (450,565) (450,565)

Foreign currency translation adjustment

Balance at Jul. 31, 2019 $ 5,424 $ 8,832,590 $ (304) $ (7,204,568) $ 1,633,142

Balance, shares at Jul. 31, 2019 5,423,956

X

- References
No definition available.
+ Details

Name: ntrb_StockIssuedDuringPeriodIssuanceOfWarrantsForServices

Namespace Prefix: ntrb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 35
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118948100&loc=d3e30304-110892

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,d)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of stock issued during the period pursuant to acquisitions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued pursuant to acquisitions during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 44 R1.htm IDEA: XBRL DOCUMENT v3.19.2

Document and Entity Information - shares
6 Months Ended

Jul. 31, 2019

Sep. 11, 2019

Document and Entity Information [Abstract]

Entity Registrant Name Nutriband Inc.

Entity Central Index Key 0001676047

Amendment Flag false

Current Fiscal Year End Date --01-31

Document Type 10-Q

Document Period End Date Jul. 31, 2019

Document Fiscal Year Focus 2020

Document Fiscal Period Focus Q2

Entity Filer Category Non-accelerated Filer

Entity Current Reporting Status Yes

Entity Small Business true

Entity Emerging Growth Company true

Entity Ex Transition Period true

Entity Shell Company false

Entity Common Stock, Shares Outstanding 5,423,956

Entity Interactive Data Current No

Entity Incorporation State Country Code NV

Entity File Number 000-55654

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ntrb_DocumentAndEntityInformationAbstract

Namespace Prefix: ntrb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R9.htm IDEA: XBRL DOCUMENT v3.19.2

Property and Equipment
6 Months Ended

Jul. 31, 2019

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT
3. PROPERTY AND EQUIPMENT

July 31, January 31,

2019 2018

Lab equipment $ 144,585 $ 144,585

Furniture, fixtures and equipment 19,643 19,643

164,228 164,228

Less: Accumulated depreciation (35,640 ) (18,081 )

Net Property and Equipment $ 128,588 $ 146,147

Depreciation expense amounted to $17,559 and $347 for the six months ended July 31, 2019 and 2018, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 47 0001213900-19-017900-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-19-017900-xbrl.zip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endXML 48 R13.htm IDEA: XBRL DOCUMENT v3.19.2 Related Party Transactions 6 Months Ended Jul. 31, 2019 Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS 7. RELATED PARTY TRANSACTIONS a) The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. See Note 4 in connection with the terms of the acquisition of 4P Therapeutics from the former owner. The former owner was not a director of the Company when the acquisition agreement was signed. b) During the six months ended July 31, 2018, the Company issued: (i) 68,000 shares of common stock, valued at $1,419,300, issued to executive officers and their affiliates; (ii) 7,500 shares of common stock, valued at $222,000, issued to the Company's independent directors; (iii) 2,500 shares of common stock, valued at $74,000, issued to the Company's advisory board member; and (iv) 2,500 shares of common stock, valued at $48,600, issued to a non-affiliated party for services. c) On February 19, 2019, the Company granted an executive officer an option to purchased 25,000 shares of the Company's common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise. The fair value of the warrant on the date of grant using the Black Scholes model was $252,700 and was expensed during the six months ended July 31, 2019. The warrant expired unexercised on May 19, 2019. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -URI http://asc.fasb.org/topic&trid=2122745 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 49 R17.htm IDEA: XBRL DOCUMENT v3.19.2 Contingencies 6 Months Ended Jul. 31, 2019 Commitments and Contingencies Disclosure [Abstract] CONTINGENCIES 11. CONTINGENCIES On July 27, 2018, the Company commenced an action in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc., Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without Notice and a Motion for Prejudgment Writ of Replevin arising from the Company's decision to seek to rescind for misrepresentation the agreement by which the Company acquired advanced Health Brans, Inc. for 1,250,000 shares of common stock valued at $2,500,000 and seek return of the shares. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against the defendants. Defendants Kalmar, Murphy, Polly-Murphy, and Baker have filed a Motion to Dismiss our Verified Complaint, Motion to Dissolve Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019, the court in the Advanced Health Brands, Inc. litigation dismissed the Company's complaint with prejudice, and directed the defendants to assign the Company within 30 days, the six patents never duly transferred to the Company. On February 1, 2019, the Company appealed the court's order. In November 2018, one of the defendants returned the 50,000 shares that had been issued to her, and these shares were cancelled as of January 31, 2019. On August 22, 2018, four of the defendants in the Florida action described in the previous paragraph filed a complaint against the Company in the Franklin County, Ohio Court of Common Pleas seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition agreement. The parties have agreed to a stay pending the outcome of the Florida litigation. On April 29, 2019, the Company filed a securities fraud action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Advanced Health Brands and TD Therapeutic, Inc. In the complaint the Company alleges that in 2017, the defendants fraudulently and deceitfully obtained 1,250,000 shares of common stock by orchestrating a months-long scheme to defraud us. We are seeking the return of the 1,200,000 shares of common stock and monetary damages resulting from the defendants' fraudulent conduct. The defendants filed a motion to dismiss. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -URI http://asc.fasb.org/topic&trid=2127136 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -URI http://asc.fasb.org/topic&trid=2144648 + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 50 R34.htm IDEA: XBRL DOCUMENT v3.19.2 Acquisition of Business (Details) - USD ($) Aug. 01, 2018 Jul. 31, 2019 Jan. 31, 2019 Fair Value Recognized On Acquisition Equipment $ 160,065 Customer base 136,500 Intellectual property 191,900 Trademark 42,300 Goodwill 1,719,235 $ 1,719,235 $ 1,719,235 Net assets acquired 2,250,000 Satisfied by: Common stock issued (1,850,000) Cash outflows on acquisition $ (400,000) X - ReferencesNo definition available. + Details Name: ntrb_BusinessAcquisitionCommonStockIssued Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTrademark. + ReferencesNo definition available. + Details Name: ntrb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsTradeMark Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: ntrb_SatisfiedByAbstract Namespace Prefix: ntrb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585 + Details Name: us-gaap_CashAcquiredFromAcquisition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 51 R30.htm IDEA: XBRL DOCUMENT v3.19.2 Summary of Significant Accounting Policies (Details Textual) - USD ($) 6 Months Ended Jul. 31, 2019 Jul. 31, 2018 Feb. 02, 2019 Jan. 31, 2019 Summary of Significant Accounting Policies (Textual) Potential shares of common stock 57,500 182,500 Right of use asset-net $ 19,218 Operating lease liability $ 19,652 Intangibles assets estimated useful lives 10 years Leases [Member] Summary of Significant Accounting Policies (Textual) Right of use asset-net $ 28,827 Operating lease liability $ 28,827 Maximum [Member] Summary of Significant Accounting Policies (Textual) Property plant and equipment 5 years Minimum [Member] Summary of Significant Accounting Policies (Textual) Property plant and equipment 3 years X - ReferencesNo definition available. + Details Name: ntrb_SummaryOfSignificantAccountingPoliciesTextualAbstract Namespace Prefix: ntrb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ntrb_LeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R38.htm IDEA: XBRL DOCUMENT v3.19.2 Intangible Assets and Goodwill (Details 1) - USD ($) 6 Months Ended Jul. 31, 2019 Jan. 31, 2019 Total Intangible Assets, Net $ 333,235 $ 351,770 Intangible Assets [Member] Intellectual property 234,200 Accumulated amortization (23,815) Book value at July 31, 2019 210,385 Customer base 136,500 Accumulated amortization (13,650) Book value at July 31, 2019 122,850 Total Intangible Assets, Net $ 333,235 X - DefinitionAccumulated amortization of customer base. + ReferencesNo definition available. + Details Name: ntrb_CustomerBaseAccumulatedAmortization Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCustomer base, Gross. + ReferencesNo definition available. + Details Name: ntrb_CustomerBaseGross Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCustomer base, Net. + ReferencesNo definition available. + Details Name: ntrb_CustomerBaseNet Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAccumulated amortization of intellectual property. + ReferencesNo definition available. + Details Name: ntrb_IntellectualPropertyAccumulatedAmortization Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIntellectual property, Gross, + ReferencesNo definition available. + Details Name: ntrb_IntellectualPropertyGross Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIntellectual property, Net. + ReferencesNo definition available. + Details Name: ntrb_IntellectualPropertyNet Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R50.htm IDEA: XBRL DOCUMENT v3.19.2 Subsequent Events (Details) Aug. 14, 2019 USD ($) Subsequent Events (Textual) Total loans from minority stockholder $ 140,000 Additional minority stockholder $ 50,000 X - ReferencesNo definition available. + Details Name: ntrb_SubsequentEventsTextualAbstract Namespace Prefix: ntrb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAs of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 3A -Subparagraph (16)(c) -URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 3A -Subparagraph 15 -URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 3A -Subparagraph (12)(c) -URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 3A -Subparagraph 14 -URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764 + Details Name: us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncontrolling interests which are redeemable by the parent entity, classified as other equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 3A -Subparagraph (12)(c) -URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 3A -Subparagraph 15 -URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 3A -Subparagraph (16)(c) -URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 3A -Subparagraph 14 -URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764 + Details Name: us-gaap_RedeemableNoncontrollingInterestEquityOtherCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 54 R8.htm IDEA: XBRL DOCUMENT v3.19.2 Summary of Significant Accounting Policies 6 Months Ended Jul. 31, 2019 Summary Of Significant Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The consolidated balance sheet as of July 31, 2019 and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. The consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods pursuant to Rule 8-03 of Regulation S-X, and consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations, changes in stockholders' equity and cash flows for all periods presented have been made. The information for the consolidated balance sheet as of January 31, 2019 was derived from audited financial statements of the Company. The Company’s significant accounting policies are found below. These policies should be read in conjunction with Note 1 in the Company’s audited financial statements for the year ended January 31, 2019. Principles of Consolidation The consolidated financial statements of the Company include the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Revenue Recognition The Company recognized revenue in accordance with Topic 606 “Revenue from Contracts with Customers. Topic 606 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic 606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Upon adoption, Topic 606 replaced most existing revenue recognition guidance in U.S. GAAP. The adoption of Topic the new revenue recognition standards did not have any impact on its consolidated financial statements since the Company did not recognize any revenue prior to the third quarter of 2018, and all revenue is recognized pursuant to Topic 606. Revenue Service Types The following is a description of the Company’s revenue service types, which include professional services and sale of goods: ● Professional services include contract research and development related services with clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged. ● Sales revenues are derived from the sale of products. To date, sales related to consumer products sold to the Company’s South Korean distributor. Upon receipt of a purchase order, the Company has the order filled and shipped. Contracts with Customers A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) the Company determines that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue types, the performance obligation is satisfied at different times. The Company‘s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When the Company performs professional service work, it recognizes revenue when it has the right to invoice the customer for the work completed, which typically occurs on a monthly basis for the work performed during that month. All revenue recognized in the statement of operations is revenue from contracts with customers. Disaggregation of Revenues The Company disaggregates its revenue from contracts with customers by service type and by geographical location. The following tables set forth revenue by service type and by geographical location. Revenue by service type: Three months ended July 31, Six months ended July 31, 2019 2018 2019 2018 Sale of goods $ - $ - $ 142,450 $ - Services 74,913 - 126,053 - Total $ 74,913 $ - $ 268,503 $ - Revenue by geographic location: Three months ended July 31, Six months ended July 31, 2019 2018 2019 2018 United States $ 74,913 $ - $ 126,053 $ - Non-United States - - 142,450 - Total $ 74,913 $ - $ 268,503 $ - Property, Plant and Equipment The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 5 years as follows: Lab equipment 5 years Furniture, fixtures and equipment 3 years Intangibles Assets Intangibles assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisition in 2018 has also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years. Goodwill Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceed their fair value. The Company does not amortize goodwill in accordance with ASC 350. Long-lived Assets Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value. Earnings per Share Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of July 31, 2019 and 2018, there were 57,500 and 182,500 common stock equivalents outstanding, respectively, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive. Stock-Based Compensation ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). For the six months ended July 31, 2018, the Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity - Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. As of February 1, 2019, pursuant to ASU 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees. Leases In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance. The Company adopted ASU 2016-02 as amended effective February 1, 2019 using the modified retrospective approach. In connection with the adoption, the Company elected to utilize the Comparative Under 840 Option whereby the Company will continue to present prior period financial statements and disclosures under ASC 840. In addition, the Company elected the transition package of three practical expedients permitted under the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and initial direct costs. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting. Adoption of the new standard resulted in the recording of right-to-use assets in the amount of $28,827 and lease liabilities related to operating leases in the amount of $28,827 on the Company’s consolidated balance sheet as of February 1, 2019. See Note 10, Leases, for Topic 842 disclosures in connection with the adoption of ASU 2016-02. Recent Accounting Standards The Company has implemented all new pronouncements, including the adoption of ASC 842 and 718, that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements or results of operations. X - ReferencesNo definition available. + Details Name: ntrb_SummaryOfSignificantAccountingPoliciesAbstract Namespace Prefix: ntrb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 55 R4.htm IDEA: XBRL DOCUMENT v3.19.2 Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) 3 Months Ended 6 Months Ended Jul. 31, 2019 Jul. 31, 2018 Jul. 31, 2019 Jul. 31, 2018 Income Statement [Abstract] Revenue $ 74,913 $ 268,503 Costs and expenses: Cost of revenues 117,959 316,753 Selling, general and administrative expenses 406,566 1,878,772 974,523 2,326,870 Total Costs and Expenses 524,525 1,878,772 1,291,276 2,326,870 Loss from operations (449,612) (1,878,772) (1,022,773) (2,326,870) Other income (expense) Interest expense (953) (1,145) Loss from operations before provision for income taxes (450,565) (1,878,772) (1,023,918) (2,326,870) Provision for income taxes Net loss $ (450,565) $ (1,878,772) $ (1,023,918) $ (2,326,870) Net loss per share of common stock-basic and diluted $ (0.08) $ (0.36) $ (0.19) $ (0.44) Weighted average shares of common stock outstanding - basic and diluted 5,423,956 5,310,033 5,423,956 5,265,406 Other Comprehensive Income (Loss): Net loss $ (573,353) $ (1,878,772) $ (1,023,918) $ (2,326,870) Foreign currency translation adjustment 252 (252) 398 Total Comprehensive Income (Loss) $ (573,353) $ (1,878,520) $ (1,024,170) $ (2,326,472) X - DefinitionThe aggregate amount of costs incurred for sales. + ReferencesNo definition available. + Details Name: ntrb_CostofSales Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256 + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 940 -SubTopic 20 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 20 -Section 45 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesNo definition available. + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (b,c) -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686 + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). + ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 56 R12.htm IDEA: XBRL DOCUMENT v3.19.2 Intangible Assets and Goodwill 6 Months Ended Jul. 31, 2019 Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS AND GOODWILL 6. INTANGIBLE ASSETS AND GOODWILL At July 31, 2019 and January 31, 2019, intangible assets consisted of intellectual property, customer base and trademarks, net of amortization, as follows: July 31, January 31, 2019 2019 Customer base $ 136,500 $ 136,500 Intellectual property 234,200 234,200 Goodwill 1,719,235 1,719,235 Total 2,089,935 2,089,935 Less: Accumulated amortization (37,465 ) (18,930 ) Net Intangible Assets $ 2,052,470 $ 2,071,005 The value of the intangible assets, consisting of intellectual property and customer base has been recorded at their fair value by the Company after completing a valuation and are being amortized over a period of ten years. Amortization expense for the six months ended July 31, 2019 and 2018 was $18,535 and $-0- respectively. No value has been given to the potential royalty payable to the former owner since the royalty is contingent upon the Company generating revenue from any source and there is no marketable product and there are material uncertainties, including the need for FDA approval, as to whether or when any revenue will be generated from the intellectual property subject to the royalty. If any royalties are paid to the former owner of 4P Therapeutics, the royalties will be expensed as incurred and treated as a cost of revenue. Intangible assets consist of: Intellectual property $ 234,200 Accumulated amortization (23,815 ) Book value at July 31, 2019 $ 210,385 Customer base $ 136,500 Accumulated amortization (13,650 ) Book value at July 31, 2019 $ 122,850 Total Intangible Assets, Net $ 333,235 Trademarks and Intellectual Customer Estimated Amortization: Property Base Total Year Ended January 31, 2020 $ 11,710 $ 6,825 $ 18,535 2021 23,420 13,650 37,070 2022 23,420 13,650 37,070 2023 23,420 13,650 37,070 2024 and thereafter 128,415 75,075 203,490 $ 210,385 $ 122,850 $ 333,235 X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details Name: us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 57 R16.htm IDEA: XBRL DOCUMENT v3.19.2 Leases 6 Months Ended Jul. 31, 2019 Leases [Abstract] LEASES 10. LEASES The Company has operating leases for its facilities used for research and development, sales and administration. These leases have remaining lease terms of less than one year. Certain of these leases contain options to extend the term of the lease and certain of these leases contain options to terminate the lease within a specified period of time. The options to extend or terminate a lease are included in the lease term when it is reasonably likely that the Company will elect that option. The Company is not a party to any material sublease arrangements. The components of lease expense, which are included in cost of revenues and general and administrative expense, based on the underlying uses of the right of use asset, were as follows: Six Months Ended July 31, 2019 Amortization of right-of-use asset $ 9,609 Interest on lease liability 1,145 Operating lease costs - Total Lease Cost $ 10,754 Supplementary cash flow information related to leases are as follows: Six Months Ended July 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 9,609 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 28,827 Supplementary balance sheet information related to leases are as follows: Operating Leases: Operating lease right-of -use assets $ 19,218 Operating lease liabilities 19,652 Weighted-Average Remaining Lease Term: Operating leases 1.00 Weighted-Average Discount Rate: Operating leases 9.24 % Our discount rate is based on our incremental borrowing rate. Maturities of lease liabilities were as follows as of July 31, 2019: Operating Year Ending January 31, Leases 2020-remaining $ 10,320 2021-remaining 10,320 Total undiscounted cash flows 20,640 Less: imputed interest (988 ) Present value of lease liabilities $ 19,652 X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -URI http://asc.fasb.org/topic&trid=2208923 + Details Name: us-gaap_LeasesOfLesseeDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 58 R39.htm IDEA: XBRL DOCUMENT v3.19.2 Intangible Assets and Goodwill (Details 2) - USD ($) Jul. 31, 2019 Jan. 31, 2019 Year Ended January 31, 2020 $ 18,535 2021 37,070 2022 37,070 2023 37,070 2024 and thereafter 203,490 Total amortization 333,235 $ 351,770 Trademark and Intellectual Property [Member] Year Ended January 31, 2020 11,710 2021 23,420 2022 23,420 2023 23,420 2024 and thereafter 128,415 Total amortization 210,385 Customer Base [Member] Year Ended January 31, 2020 6,825 2021 13,650 2022 13,650 2023 13,650 2024 and thereafter 75,075 Total amortization $ 122,850 X - DefinitionAmount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ntrb_TrademarkAndIntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R35.htm IDEA: XBRL DOCUMENT v3.19.2 Acquisition of Business (Details 1) - USD ($) 3 Months Ended 6 Months Ended Jul. 31, 2019 Jul. 31, 2018 Jul. 31, 2019 Jul. 31, 2018 Business Combinations [Abstract] Revenue $ 74,913 $ 268,503 Net loss $ (450,565) $ (1,878,772) $ (1,023,918) $ (2,326,870) Loss per share of common stock (basic and diluted) $ (0.08) $ (0.36) $ (0.19) $ (0.44) Revenue, Pro Forma $ 331,864 Net loss, Pro Forma $ (2,421,391) Loss per share of common stock (basic and diluted), Pro Forma $ (0.46) X - ReferencesNo definition available. + Details Name: ntrb_BusinessAcquisitionProFormaEarningsPerShareDilutedAndBasic Namespace Prefix: ntrb_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details Name: us-gaap_BusinessAcquisitionsProFormaRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256 + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 60 R31.htm IDEA: XBRL DOCUMENT v3.19.2 Property and Equipment (Details) - USD ($) Jul. 31, 2019 Jan. 31, 2019 Jan. 31, 2018 Property, Plant and Equipment [Line Items] Property and equipment, gross $ 164,228 $ 164,228 Less: Accumulated depreciation (35,640) (18,081) Net Property and Equipment 128,588 $ 146,147 146,147 Lab equipment [Member] Property, Plant and Equipment [Line Items] Net Property and Equipment 144,585 144,585 Furniture, fixtures and equipment [Member] Property, Plant and Equipment [Line Items] Net Property and Equipment $ 19,643 $ 19,643 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.14) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R20.htm IDEA: XBRL DOCUMENT v3.19.2 Summary of Significant Accounting Policies (Tables) 6 Months Ended Jul. 31, 2019 Summary Of Significant Accounting Policies [Abstract] Schedule of disaggregation of revenues Three months ended July 31, Six months ended July 31, 2019 2018 2019 2018 Sale of goods $ - $ - $ 142,450 $ - Services 74,913 - 126,053 - Total $ 74,913 $ - $ 268,503 $ - Three months ended July 31, Six months ended July 31, 2019 2018 2019 2018 United States $ 74,913 $ - $ 126,053 $ - Non-United States - - 142,450 - Total $ 74,913 $ - $ 268,503 $ - Schedule of property plant and equipment Lab equipment 5 years Furniture, fixtures and equipment 3 years X - DefinitionTabular disclosure of property and equipment usefull life. + ReferencesNo definition available. + Details Name: ntrb_PropertyPlantAndEquipmentUsefulLifeTextBlock Namespace Prefix: ntrb_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: ntrb_SummaryOfSignificantAccountingPoliciesAbstract Namespace Prefix: ntrb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 62 R24.htm IDEA: XBRL DOCUMENT v3.19.2 Warrants and Options (Tables) 6 Months Ended Jul. 31, 2019 Schedule of additional warrants outstanding Range of Number Remaining Contractual Exercise Price for Shares Number Exercise Price for Shares Exercise Prices Outstanding Life(Years) Outstanding Exercisable Exercisable $ 14.00 57,500 0.50 $ 14.00 57,500 $ 14.00 Stock Options [Member] Schedule of warrants Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, 2019 - $ - - $ - Granted 25,000 25.64 0.05 years 232,750 Expired/Cancelled (25,000 ) 25.64 - - Exercised - - - - Outstanding-period ending July 31, 2019 - $ - - $ - Exercisable - period ending July 31, 2019 - $ - - $ - Warrants [Member] Schedule of warrants Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, 2019 182,500 $ 6.32 0.35 years $ 4,101,000 Granted - - - - Expired/Cancelled (125,000 ) 2.80 - - Exercised - - - - Outstanding-period ending July 31, 2019 57,500 $ 14.00 0.50 years $ 1,466,250 Exercisable - period ending July 31, 2019 57,500 $ 14.00 0.50 years $ 1,466,250 X - DefinitionTabular disclosure of additional warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesNo definition available. + Details Name: ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding Namespace Prefix: ntrb_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R28.htm IDEA: XBRL DOCUMENT v3.19.2 Summary of Significant Accounting Policies (Details 1) - USD ($) 3 Months Ended 6 Months Ended Jul. 31, 2019 Jul. 31, 2018 Jul. 31, 2019 Jul. 31, 2018 Revenue by geographical location Total $ 74,913 $ 268,503 United States [Member] Revenue by geographical location Total 74,913 126,053 Non-United States [Member] Revenue by geographical location Total $ 142,450 X - ReferencesNo definition available. + Details Name: ntrb_RevenueByGeographicalLocationAbstract Namespace Prefix: ntrb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R49.htm IDEA: XBRL DOCUMENT v3.19.2 Contingencies (Details) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended Apr. 29, 2019 Jan. 31, 2019 Nov. 30, 2018 Jul. 27, 2018 Jul. 31, 2018 Jul. 31, 2018 Jul. 31, 2019 Contingencies (Textual) Acquired advanced shares of common stock value $ 2,500,000 $ 1,850,000 $ 1,850,000 Acquired advanced shares of common stock 1,250,000 Common stock issued 5,423,956 5,423,956 Common Stock [Member] Contingencies (Textual) Acquired advanced shares of common stock value $ 63 $ 63 Acquired advanced shares of common stock 62,500 62,500 Health Brans, Inc. [Member] Contingencies (Textual) Acquired advanced shares of common stock 1,250,000 Returned, shares 1,200,000 Advanced Health Brands [Member] | Common Stock [Member] Contingencies (Textual) Common stock issued 50,000 Shares cancelled date Jan. 31, 2019 Defendants [Member] Contingencies (Textual) Shares cancelled 50,000 X - ReferencesNo definition available. + Details Name: ntrb_ContingenciesTextualAbstract Namespace Prefix: ntrb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: ntrb_SharesforfeitedDate Namespace Prefix: ntrb_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares (or other type of equity) forfeited during the period. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_HealthBransIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ntrb_AdvancedHealthBrandsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ntrb_DefendantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R45.htm IDEA: XBRL DOCUMENT v3.19.2 Leases (Details) 6 Months Ended Jul. 31, 2019 USD ($) Leases [Abstract] Amortization of right-of-use asset $ 9,609 Interest on lease liability 1,145 Operating lease costs Total Lease Cost $ 10,754 X - DefinitionAmount of interest expense on lease liability. + ReferencesNo definition available. + Details Name: ntrb_LeaseInterestExpense Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest paid on lease liability. + ReferencesNo definition available. + Details Name: ntrb_OperatingLeaseInterestPaymentOnLiability Namespace Prefix: ntrb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe expense charged against earnings for the periodic recognition of capitalized leases. This element may apply to energy companies that lease mineral producing properties and to other enterprises that capitalize property, plant, or equipment obtained through capital leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84164758&loc=d3e45031-112735 + Details Name: us-gaap_AmortizationOfLeasedAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 66 R41.htm IDEA: XBRL DOCUMENT v3.19.2 Related Party Transactions (Details) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended Feb. 19, 2019 Jul. 31, 2018 Jul. 31, 2018 Related Party Transactions (Textual) Shares of common stock, value $ 1,000,000 $ 1,000,000 Executives [Member] Related Party Transactions (Textual) Shares of common stock, issued 68,000 Shares of common stock, value $ 1,419,300 Director [Member] Related Party Transactions (Textual) Shares of common stock, issued 7,500 Shares of common stock, value $ 222,000 Advisory Board [Member] Related Party Transactions (Textual) Shares of common stock, issued 2,500 Shares of common stock, value $ 74,000 Non-affiliated [Member] Related Party Transactions (Textual) Shares of common stock, issued 2,500 Shares of common stock, value $ 48,600 Black Scholes [Member] Related Party Transactions (Textual) Stock, description The Company granted an executive officer an option to purchased 25,000 shares of the Company's common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise. The fair value of the warrant on the date of grant using the Black Scholes model was $252,700 and was expensed during the six months ended July 31, 2019. The warrant expired unexercised on May 19, 2019. X - ReferencesNo definition available. + Details Name: ntrb_RelatedPartyTransactionsTextualAbstract Namespace Prefix: ntrb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684 + Details Name: us-gaap_SaleOfStockDescriptionOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ntrb_AdvisoryBoardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ntrb_NonAffiliatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type:

Summary of Significant Accounting Policies (Details 2)	6 Months Ended
Summary of Significant Accounting Policies (Details 2)	Jul. 31, 2019
Lab equipment [Member]
Property, Plant and Equipment	5 years
Furniture, fixtures and equipment [Member]
Property, Plant and Equipment	3 years

Warrants and Options (Details 1) - 14.00 [Member]	6 Months Ended
Warrants and Options (Details 1) - 14.00 [Member]	Jul. 31, 2019 $ / shares shares
Range of Exercise Prices	14.00
Number Outstanding	57,500
Remaining Contractual Life (Years)	6 months
Exercise Price for Shares Outstanding \| $ / shares	$ 14.00
Number Exercisable	57,500
Exercise Price for Shares Exercisable \| $ / shares	$ 14.00

Intangible Assets and Goodwill (Details Textual) - USD ($)	6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Intangible Assets and Goodwill (Textual)
Amortization expense of intangible assets	$ 18,535	$ 0

Leases (Details 3)	Jul. 31, 2019 USD ($)
Leases [Abstract]
2020-remaining	$ 10,320
2021-remaining	10,320
Total undiscounted cash flows	20,640
Less: imputed interest	(988)
Present value of lease liabilities	$ 19,652

Unaudited Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Income(Loss)	Accumulated Deficit	Common stock to be issued	Total
Balance at Jan. 31, 2018	$ 5,219	$ 2,966,145	$ (446)	$ (2,849,410)		$ 121,508
Balance, shares at Jan. 31, 2018	5,219,275
Issuance of common stock for services	$ 1,850,000	1,763,870				1,763,950
Issuance of common stock for services, shares	62,500
Sale of common stock for cash	$ 63	999,937				1,000,000
Sale of common stock for cash, shares	62,500
Common stock issued upon the exercise of warrants	$ 31	499,969				500,000
Common stock issued upon the exercise of warrants, shares	31,250
Common stock issued for acquisition	$ 63	1,849,937				1,850,000
Common stock issued for acquisition, shares	62,500
Net loss				(2,326,870)		(2,326,870)
Foreign currency translation adjustment			398			398
Balance at Jul. 31, 2018	$ 5,456	8,079,858	(48)	(5,176,280)		2,908,986
Balance, shares at Jul. 31, 2018	5,456,025
Balance at Apr. 30, 2018	$ 5,219	2,966,145	(300)	(3,297,508)	277,500	(48,944)
Balance, shares at Apr. 30, 2018	5,219,275
Issuance of common stock for services	$ 80	1,763,870			(277,500)	1,486,450
Issuance of common stock for services, shares	80,500
Sale of common stock for cash	$ 63	999,937				1,000,000
Sale of common stock for cash, shares	62,500
Common stock issued upon the exercise of warrants	$ 31	499,969				500,000
Common stock issued upon the exercise of warrants, shares	31,250
Common stock issued for acquisition	$ 63	1,849,937				1,850,000
Common stock issued for acquisition, shares	62,500
Net loss				(1,878,772)		(1,878,772)
Foreign currency translation adjustment			252			252
Balance at Jul. 31, 2018	$ 5,456	8,079,858	(48)	(5,176,280)		2,908,986
Balance, shares at Jul. 31, 2018	5,456,025
Balance at Jan. 31, 2019	$ 5,424	8,579,890	(52)	(6,180,650)		2,404,612
Balance, shares at Jan. 31, 2019	5,423,956
Issuance of warrants for services		252,700				252,700
Net loss				(1,023,918)		(1,023,918)
Foreign currency translation adjustment			(252)			(252)
Balance at Jul. 31, 2019	$ 5,424	8,832,590	(304)	(7,204,568)		1,633,142
Balance, shares at Jul. 31, 2019	5,423,956
Balance at Apr. 30, 2019	$ 5,424	8,832,590	(304)	(6,754,003)		2,083,707
Balance, shares at Apr. 30, 2019	5,423,956
Net loss				(450,565)		(450,565)
Foreign currency translation adjustment
Balance at Jul. 31, 2019	$ 5,424	$ 8,832,590	$ (304)	$ (7,204,568)		$ 1,633,142
Balance, shares at Jul. 31, 2019	5,423,956

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jul. 31, 2019	Sep. 11, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Nutriband Inc.
Entity Central Index Key	0001676047
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Document Type	10-Q
Document Period End Date	Jul. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,423,956
Entity Interactive Data Current	No
Entity Incorporation State Country Code	NV
Entity File Number	000-55654

Acquisition of Business (Details) - USD ($)	Aug. 01, 2018	Jul. 31, 2019	Jan. 31, 2019
Fair Value Recognized On Acquisition
Equipment	$ 160,065
Customer base	136,500
Intellectual property	191,900
Trademark	42,300
Goodwill	1,719,235	$ 1,719,235	$ 1,719,235
Net assets acquired	2,250,000
Satisfied by:
Common stock issued	(1,850,000)
Cash outflows on acquisition	$ (400,000)

Summary of Significant Accounting Policies (Details Textual) - USD ($)	6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Feb. 02, 2019	Jan. 31, 2019
Summary of Significant Accounting Policies (Textual)
Potential shares of common stock	57,500	182,500
Right of use asset-net	$ 19,218
Operating lease liability	$ 19,652
Intangibles assets estimated useful lives	10 years
Leases [Member]
Summary of Significant Accounting Policies (Textual)
Right of use asset-net			$ 28,827
Operating lease liability			$ 28,827
Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Property plant and equipment	5 years
Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Property plant and equipment	3 years

Subsequent Events (Details)	Aug. 14, 2019 USD ($)
Subsequent Events (Textual)
Total loans from minority stockholder	$ 140,000
Additional minority stockholder	$ 50,000

Intangible Assets and Goodwill (Details 2) - USD ($)	Jul. 31, 2019	Jan. 31, 2019
Year Ended January 31,
2020	$ 18,535
2021	37,070
2022	37,070
2023	37,070
2024 and thereafter	203,490
Total amortization	333,235	$ 351,770
Trademark and Intellectual Property [Member]
Year Ended January 31,
2020	11,710
2021	23,420
2022	23,420
2023	23,420
2024 and thereafter	128,415
Total amortization	210,385
Customer Base [Member]
Year Ended January 31,
2020	6,825
2021	13,650
2022	13,650
2023	13,650
2024 and thereafter	75,075
Total amortization	$ 122,850

Acquisition of Business (Details 1) - USD ($)	3 Months Ended		6 Months Ended
Acquisition of Business (Details 1) - USD ($)	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Business Combinations [Abstract]
Revenue	$ 74,913		$ 268,503
Net loss	$ (450,565)	$ (1,878,772)	$ (1,023,918)	$ (2,326,870)
Loss per share of common stock (basic and diluted)	$ (0.08)	$ (0.36)	$ (0.19)	$ (0.44)
Revenue, Pro Forma				$ 331,864
Net loss, Pro Forma				$ (2,421,391)
Loss per share of common stock (basic and diluted), Pro Forma				$ (0.46)

Property and Equipment (Details) - USD ($)	Jul. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 164,228		$ 164,228
Less: Accumulated depreciation	(35,640)		(18,081)
Net Property and Equipment	128,588	$ 146,147	146,147
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Net Property and Equipment	144,585		144,585
Furniture, fixtures and equipment [Member]
Property, Plant and Equipment [Line Items]
Net Property and Equipment	$ 19,643		$ 19,643

Contingencies (Details) - USD ($)			1 Months Ended		3 Months Ended	6 Months Ended
Contingencies (Details) - USD ($)	Apr. 29, 2019	Jan. 31, 2019	Nov. 30, 2018	Jul. 27, 2018	Jul. 31, 2018	Jul. 31, 2018	Jul. 31, 2019
Contingencies (Textual)
Acquired advanced shares of common stock value				$ 2,500,000	$ 1,850,000	$ 1,850,000
Acquired advanced shares of common stock				1,250,000
Common stock issued		5,423,956					5,423,956
Common Stock [Member]
Contingencies (Textual)
Acquired advanced shares of common stock value					$ 63	$ 63
Acquired advanced shares of common stock					62,500	62,500
Health Brans, Inc. [Member]
Contingencies (Textual)
Acquired advanced shares of common stock	1,250,000
Returned, shares	1,200,000
Advanced Health Brands [Member] \| Common Stock [Member]
Contingencies (Textual)
Common stock issued			50,000
Shares cancelled date			Jan. 31, 2019
Defendants [Member]
Contingencies (Textual)
Shares cancelled		50,000

Leases (Details)	6 Months Ended
Leases (Details)	Jul. 31, 2019 USD ($)
Leases [Abstract]
Amortization of right-of-use asset	$ 9,609
Interest on lease liability	1,145
Operating lease costs
Total Lease Cost	$ 10,754

Related Party Transactions (Details) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
Related Party Transactions (Details) - USD ($)	Feb. 19, 2019	Jul. 31, 2018	Jul. 31, 2018
Related Party Transactions (Textual)
Shares of common stock, value		$ 1,000,000	$ 1,000,000
Executives [Member]
Related Party Transactions (Textual)
Shares of common stock, issued			68,000
Shares of common stock, value			$ 1,419,300
Director [Member]
Related Party Transactions (Textual)
Shares of common stock, issued			7,500
Shares of common stock, value			$ 222,000
Advisory Board [Member]
Related Party Transactions (Textual)
Shares of common stock, issued			2,500
Shares of common stock, value			$ 74,000
Non-affiliated [Member]
Related Party Transactions (Textual)
Shares of common stock, issued			2,500
Shares of common stock, value			$ 48,600
Black Scholes [Member]
Related Party Transactions (Textual)
Stock, description	The Company granted an executive officer an option to purchased 25,000 shares of the Company's common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise. The fair value of the warrant on the date of grant using the Black Scholes model was $252,700 and was expensed during the six months ended July 31, 2019. The warrant expired unexercised on May 19, 2019.